iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/38958149/
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 3;7(7):CD013425.
doi: 10.1002/14651858.CD013425.pub2.

Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders

Khasan Ibragimov  1   2 , Gregory Peter Keane  3 , Cristina Carreño Glaría  4 , Jie Cheng  5 , Augusto Eduardo Llosa  2   4
Affiliations
Review

Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders

Khasan Ibragimov et al. Cochrane Database Syst Rev. .

Abstract

Background: Schizophrenia is often a severe and disabling psychiatric disorder. Antipsychotics remain the mainstay of psychotropic treatment for people with psychosis. In limited resource and humanitarian contexts, it is key to have several options for beneficial, low-cost antipsychotics, which require minimal monitoring. We wanted to compare oral haloperidol, as one of the most available antipsychotics in these settings, with a second-generation antipsychotic, olanzapine.

Objectives: To assess the clinical benefits and harms of haloperidol compared to olanzapine for people with schizophrenia and schizophrenia-spectrum disorders.

Search methods: We searched the Cochrane Schizophrenia study-based register of trials, which is based on monthly searches of CENTRAL, CINAHL, ClinicalTrials.gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed and WHO ICTRP. We screened the references of all included studies. We contacted relevant authors of trials for additional information where clarification was required or where data were incomplete. The register was last searched on 14 January 2023.

Selection criteria: Randomised clinical trials comparing haloperidol with olanzapine for people with schizophrenia and schizophrenia-spectrum disorders. Our main outcomes of interest were clinically important change in global state, relapse, clinically important change in mental state, extrapyramidal side effects, weight increase, clinically important change in quality of life and leaving the study early due to adverse effects.

Data collection and analysis: We independently evaluated and extracted data. For dichotomous outcomes, we calculated risk ratios (RR) and their 95% confidence intervals (CI) and the number needed to treat for an additional beneficial or harmful outcome (NNTB or NNTH) with 95% CI. For continuous data, we estimated mean differences (MD) or standardised mean differences (SMD) with 95% CIs. For all included studies, we assessed risk of bias (RoB 1) and we used the GRADE approach to create a summary of findings table.

Main results: We included 68 studies randomising 9132 participants. We are very uncertain whether there is a difference between haloperidol and olanzapine in clinically important change in global state (RR 0.84, 95% CI 0.69 to 1.02; 6 studies, 3078 participants; very low-certainty evidence). We are very uncertain whether there is a difference between haloperidol and olanzapine in relapse (RR 1.42, 95% CI 1.00 to 2.02; 7 studies, 1499 participants; very low-certainty evidence). Haloperidol may reduce the incidence of clinically important change in overall mental state compared to olanzapine (RR 0.70, 95% CI 0.60 to 0.81; 13 studies, 1210 participants; low-certainty evidence). For every eight people treated with haloperidol instead of olanzapine, one fewer person would experience this improvement. The evidence suggests that haloperidol may result in a large increase in extrapyramidal side effects compared to olanzapine (RR 3.38, 95% CI 2.28 to 5.02; 14 studies, 3290 participants; low-certainty evidence). For every three people treated with haloperidol instead of olanzapine, one additional person would experience extrapyramidal side effects. For weight gain, the evidence suggests that there may be a large reduction in the risk with haloperidol compared to olanzapine (RR 0.47, 95% CI 0.35 to 0.61; 18 studies, 4302 participants; low-certainty evidence). For every 10 people treated with haloperidol instead of olanzapine, one fewer person would experience weight increase. A single study suggests that haloperidol may reduce the incidence of clinically important change in quality of life compared to olanzapine (RR 0.72, 95% CI 0.57 to 0.91; 828 participants; low-certainty evidence). For every nine people treated with haloperidol instead of olanzapine, one fewer person would experience clinically important improvement in quality of life. Haloperidol may result in an increase in the incidence of leaving the study early due to adverse effects compared to olanzapine (RR 1.99, 95% CI 1.60 to 2.47; 21 studies, 5047 participants; low-certainty evidence). For every 22 people treated with haloperidol instead of olanzapine, one fewer person would experience this outcome. Thirty otherwise relevant studies and several endpoints from 14 included studies could not be evaluated due to inconsistencies and poor transparency of several parameters. Furthermore, even within studies that were included, it was often not possible to use data for the same reasons. Risk of bias differed substantially for different outcomes and the certainty of the evidence ranged from very low to low. The most common risks of bias leading to downgrading of the evidence were blinding (performance bias) and selective reporting (reporting bias).

Authors' conclusions: Overall, the certainty of the evidence was low to very low for the main outcomes in this review, making it difficult to draw reliable conclusions. We are very uncertain whether there is a difference between haloperidol and olanzapine in terms of clinically important global state and relapse. Olanzapine may result in a slightly greater overall clinically important change in mental state and in a clinically important change in quality of life. Different side effect profiles were noted: haloperidol may result in a large increase in extrapyramidal side effects and olanzapine in a large increase in weight gain. The drug of choice needs to take into account side effect profiles and the preferences of the individual. These findings and the recent inclusion of olanzapine alongside haloperidol in the WHO Model List of Essential Medicines should increase the likelihood of it becoming more easily available in low- and middle- income countries, thereby improving choice and providing a greater ability to respond to side effects for people with lived experience of schizophrenia. There is a need for additional research using appropriate and equivalent dosages of these drugs. Some of this research needs to be done in low- and middle-income settings and should actively seek to account for factors relevant to these. Research on antipsychotics needs to be person-centred and prioritise factors that are of interest to people with lived experience of schizophrenia.

Trial registration: ClinicalTrials.gov NCT01164059 NCT01123408 NCT00191555 NCT01052389 NCT00534183 NCT00485901 NCT00419653 NCT01193166.

PubMed Disclaimer

Conflict of interest statement

Khasan Ibragimov: none known Gregory Keane: none known Cristina Carreño: none known Jie Cheng: none known Augusto Llosa: none known

Update of

  • doi: 10.1002/14651858.CD013425

Similar articles

See all similar articles

References

References to studies included in this review

Altamura (HGBQ) 1999 {published and unpublished data}5242
    1. Altamura AC, Eli Lilly Data Compilers. HGBQ - Olanzapine verus haloperidol in partial responder schizophrenic patients. Supplied by Eli Lilly 2000.
    1. Altamura AC, Velona I, Curreli R, Bravi D. Olanzapine in the treatment of paranoid schizophrenia. European Neuropsychopharmacology 1999;9(Suppl 5):S297. [CSZG: 5951]
    1. Altamura AC, Velona I, Curreli R, Mundo E, Bravi D. Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. International Journal of Psychiatry in Clinical Practice 2002;6(2):107-11. [CSZG: 10021] [EMBASE  2002201401; CN-00443300.] - PubMed
Avasthi 2001 {published data only}7309
    1. Avasthi A, Kulhara P, Kakkar N. Olanzapine in the treatment of schizophrenia: an open label comparative trial from North India. Indian Journal of Psychiatry 2001;43(3):257-63. [CSZG: 10100] - PMC - PubMed
Barak 2002 {published data only}6903
    1. Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2002;26:1199-202. [CSZG: 9250] [MEDLINE: ] [PMID 12452546] - PubMed
Beasley (E003) 1997 {published and unpublished data}14618
    1. Baker R W, Julier B, Stauffer V. Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo. In: 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001. [CSZG: 7566]
    1. Beasley CM Jr, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. A randomized, double-blind comparison of the incidence of tardive dyskinesia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry 1999;174:23-30. [CSZG: 3447] - PubMed
    1. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 1997;7:125-37. [CSZG: 1844] - PubMed
    1. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. Journal of Clinical Psychiatry 1997;58(Suppl 10):13-7. - PubMed
    1. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophrenia Research 1998;29(1-2):28. [CSZG: 9191]
Beasley (HGAD) 1996a {published and unpublished data}5582
    1. Baker R W, Julier B, Stauffer V. Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo. In: 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. Vol. 2. 2001. [CSZG: 7566]
    1. Baker RW, Ames D, Umbricht DSG, Chengappa KNR, Schooler NR. Obsessive-compulsive symptoms in schizophrenia - a comparison of olanzapine and placebo. Psychopharmacology Bulletin 1996;32:89-93. [CSZG: 479] - PubMed
    1. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23. [CSZG: 1026] - PubMed
    1. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. Journal of Clinical Psychiatry 1997;58(Suppl 10):13-7. [CSZG: 9984] - PubMed
    1. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophrenia Research 1998;29(1-2):28. [CSZG: 9191]
Bernardo (HGDD) 2001 {published data only}6127
    1. Bernardo M, Parellada E, Lomena F, Catafau AM, Font M, Gomez JC, et al. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Research 2001;107:87-97. [CSZG: 8180] [MEDLINE: ] - PubMed
Boulay 2002 {published data only}
    1. Boulay L. Contrasting the effects of haloperidol and olanzapine on attention and working memory in schizophrenia: a double-blind flexible dose study [[in Partial fulfillment of the requirements for the degree of Doctor of Philosophy]]. National Library of Canada 2003. [ISBN: 0-612-83513-8]
    1. Boulay LJ, Labelle A, Bourget D, Robertson S, Habib R, Tessier P, et al. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol. Cognitive Neuropsychiatry 2007;12(4):322-38. [DOI: 10.1080/13546800601069534] [PMID: PMID: 17558641] - DOI - PubMed
Buchanan 2003 {published data only}
    1. Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold J, Carpenter WT, et al. Olanzapine treatment of residual positive and negative symptoms. Journal of Psychiatry 2005;162(1):124-9. [DOI: 10.1176/appi.ajp.162.1.124] - DOI - PubMed
    1. Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold J, Carpenter WT. Olanzapine treatment of residual positive and negative symptoms. Schizophrenia Research 2003;60:275. [EMBASE: 2003241517] - PubMed
    1. Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. Journal of Psychopharmacology 2009;23(4):436-41. [DOI: 10.1177/0269881108093883] [PMID: ] - DOI - PMC - PubMed
    1. Haan L, Beveren N. Olanzapine and haloperidol for residual symptoms. American Journal of Psychiatry 2005;162(7):1392-3. [DOI: 10.1176/appi.ajp.162.7.1392] - DOI - PubMed
Chaudhry 2003 {published data only}
    1. Chaudhry HR, Kongsakon R, Ignacio JC, Raza SB, Leynes MCR, Hasanah CI, et al. Quality of life and clinical outcomes for Asian outpatients with schizophrenia: a double-blind randomised comparison of olanzapine and haloperidol. Journal of the European College of Neuropsychopharmacology 2003;13(4):S309. [CSZG: 9857] [P.2.069]
    1. Chaudhry HR, Raza SB, Ismail HC, Chan B, Ignacio JC, Rodriguez SC, et al. Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. Journal of the Medical Association of Thailand 2006;89(8):1157-70. [PMID: PMID: 17048425] - PubMed
Crespo‐Facorro 2006 {published data only}
    1. Ayesa-Arriola R, Rodríguez-Sánchez J M, Pérez-Iglesias R, Roiz-Santiáñez R, Martínez-García O, Sánchez-Moreno J, et al. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. Psychopharmacology 2013;227(4):615-25. [DOI: 10.1007/s00213-013-2994-z] [PMID: ] - DOI - PubMed
    1. Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, Pelayo-Terán JM, Fernandez-Prieto L, Leyva-Cobián F, et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Research 2008;158(2):206-16. [DOI: 10.1016/j.psychres.2006.08.005] [PMID: ] - DOI - PubMed
    1. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al. Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects. Evidence-Based Mental Health 2007;10(3):74. [PMID: ] - PubMed
    1. Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, et al. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. Journal of Psychiatric Research 2011;45(6):763-9. [DOI: 10.1016/j.jpsychires.2010.11.002] [PMID: ] - DOI - PubMed
    1. Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Ortiz V, Pelayo-Terán JM, et al. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology 2012;219(1):225-33. [DOI: 10.1007/s00213-011-2392-3] [PMID: ] - DOI - PubMed
Cui 2016e {published data only}
    1. 崔明伟, 张小波. 氟哌啶醇与奥氮平治疗精神分裂症疗效探讨. 海峡药学 2016;28(6):175-6.
de Hann 2003 {published data only}6792
    1. Haan L, Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. American Journal of Psychiatry 2003;160:303-9. [CSZG: 9253] [MEDLINE: ] [PMID 12562577] - PubMed
    1. Haan L, van-Bruggen M, Lavalaye J, Booij J, Dingemans P, Linszen D. Subjective experience and d2 receptor occupancy in patients with schizophrenia, treated with low dose olanzapine or haloperidol; a randomized double-blind study. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;3 Suppl 1:179. [CSZG: 8065]
Dhar 2010 {published data only}
    1. Dhar R, Chavan BS, Sidana A. Comparative efficacy of haloperidol and olanzapine in patients of schizophrenia: a 6 month follow up trial. JMHHB 2010;15:31-9. [https://pdfs.semanticscholar.org/7890/31a9cba833edd4d19fa35f42a8cd4a1210...]
Ding 2013 {published data only}
    1. 丁婷, 刘玉兰. Controlled study in refractory schizophrenia treatment olanzapine and haloperidol [Google Translate] [奥氮平与氟哌啶醇治疗难治性精神分裂症的对照研究]. China Journal of Health Psychology [中国健康心理学杂志] 2013;21(01):23-4.
Gründer (NeSSy) 2012 {published and unpublished data}
    1. Gruender G, Heinze M, Cordes J, Ruether E, Timm J. The "Neuroleptic Strategy Study" (NeSSy)-first vs. second generation antipsychotics for the treatment of schizophrenia. Neuropsychopharmacology 2014;39:S370-1.
    1. Gruender G, Timm J, Muehlbauer B, Handschuh D, Heinze M, Schulz C, et al. Antipsychotic Serum Concentrations in the "Neuroleptic Strategy Study"(NeSSy). Neuropsychopharmacology 2016;41:S233-4.
    1. Gründer G, Heinze M, Cordes J, Mühlbauer B, Juckel G, Schulz C, NeSSy Study Group. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry 2016;3(8):717-29. [DOI: 10.1016/S2215-0366(16)00085-7] [PMID: ] - DOI - PubMed
    1. Schulz C, Timm J, Cordes J, Gründer G, Mühlbauer B, Rüther E, et al. Patient-oriented randomisation: a new trial design applied in the Neuroleptic Strategy Study. Clinical Trials 2016;13(3):251-9. [DOI: 10.1177/1740774516639910] [PMID: ] - DOI - PubMed
    1. Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, et al. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia–findings from the randomized NeSSy trial. European Neuropsychopharmacology 2019;29(6):720-39. [DOI: 10.1177/1740774516639910] [PMID: ] - DOI - PubMed
HGCJ (Hong Kong) 1998 {published and unpublished data}14101
    1. Tran PV, Beasley CM, Tollefson GD, Creanga D, Zhang F, Wang J, et al. Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent. In: Meeting of the American Psychiatric Association. Washington, DC, USA. 1999. [CSZG: 4045]
    1. Tran PV, Beasley CM, Tollefson GD, Creanga D, Zhang F, Wang J, et al. Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent. In: World Psychiatric Association; Hamburg, Germany. 1999. [CSZG: 7053]
    1. Tran PV, Cousins LM, Creanga D, Tollefson GD, Vangala S, Wang J, et al. Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent. In: ACNP. Hawaii, USA. 1998.
    1. Tran PV, Creanga D, Zhang F, Wang J, Vangala S, Cousins L, et al. Clinical experience with olanzapine in ethnic subgroups. In: NCDEU. Boca Raton, FL, USA. 1999. [CSZG: 7042]
    1. Tran PV, Zhang F, Hwu HG, Liehmak F. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong. In: APA Annual Meeting, May 15-20, Washington, DC. 1999. [CSZG: 4049] [CSG NO. 4118]
HGCU (Taiwan) 1998 {published and unpublished data}2841
    1. Tran PV, Creanga D, Zhang F, Wang J, Vangala S, Cousins L, et al. Clinical experience with olanzapine in ethnic subgroups. In: NCDEU. Boca Raton, FL, USA. 1999. [CSZG: 7042]
    1. Tran PV, Zhang F, Hwu HG, Liehmak F. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong. In: American Psychiatric Association Annual Meeting; 1999 May 15-20; Washington DC; USA. 1999. [CSZG: 4049] [CSG NO. 4118]
    1. Zhang F, Tran PV, Taylor C, Hwu GH, Chen YS, Chang WH, et al. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong. In: World Psychiatric Association. Hamburg, Germany. 1999. [CSZG: 18834]
HGFH (Korea) 1998 {unpublished data only}
    1. HGFH Korea. Data on file. Data supplied to the Cochrane Schizophrenia Group 1999.
Hu 2014i {published data only}
    1. 胡立红. 氟哌啶醇与奥氮平治疗精神分裂症疗效和安全性. 中国卫生标准管理 2014;-(17):90-1.
Ishigooka 2001 {published data only}5738
    1. Inada T, Beasley CM, Yoko T, Walker D. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haoperidol. International Clinical Psychopharmacology 2003;18:39-48. [CSZG: 9109] - PubMed
    1. Inada T, Miura S. Favorable eps profiles of olanzapine measured by the diepss: predictive validity of this scale to differentiate the eps profiles of atypical antipsychotic drugs from conventional antipsychotic drugs in the clinical trial. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S147. [CSZG: 4748]
    1. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia Research 2002;57(2-3):227-38. [CSZG: 8571] - PubMed
    1. Ishigooka J, Hirotsu C, Kurihara M, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multi-center double-blind olanzapine trial. Psychiatry and Clinical Neurosciences 2001;55(4):403-14. [CSZG: 4470] - PubMed
Jiang 2009b {published data only}
    1. 蒋合萍, 罗毅平. Olanzapine and haloperidol in the treatment of schizophrenia comparative study of excited agitation [Google Translate] [奥氮平与氟哌啶醇治疗精神分裂症兴奋激越症状的对照研究 []. Sichuan Mental Health [四川精神卫生] 2009;22(1):43-4.
Jones 1998 (P022) {published and unpublished data}3314
    1. Canadian Cognition and Outcome Study Group. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone or haloperidol. Schizophrenia Research 1998;29:132-3. - PubMed
    1. David SR, Purdon S, Jones BD, Stip E, Labelle A, Breier AF, et al. Olanzapine versus risperidone versus haloperidol in early illness schizophrenia. Education improves outcomes in MDD. In: 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA. 1999. [CSZG: 3502] [MEDLINE: ]
    1. Jones B, Tollefson G. Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia. Schizophrenia Research 1998;29:150-1. [CSZG: 7215]
    1. Jones B. Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia. In: 151st Annual Meeting of American Psychiatric Association; May 30-June 4; Toronto; ON, Canada. 1998. [CSZG: 3408]
    1. Jones B. Treatment of cognitive deficits with antipsychotic drugs. Neurobiology of Aging (Abstracts of 6th International Conference on Alzheimer's Disease and Related Disorders; 1998 Jul 18-23; Amsterdam, the Netherlands) 1998;4S:S152-3. [CSZG: 8662]
Kahn (EUFEST) 2005 {published and unpublished data}68736636
    1. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Eufest Study Group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 2009;115(2-3):97-103. [DOI: 10.1016/j.schres.2009.09.019] - DOI - PubMed
    1. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 2009;166(6):675-82. [DOI: 10.1176/appi.ajp.2008.08060806] - DOI - PubMed
    1. Fleischhacker WW, Keet IP, Kahn RS, EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophrenia Research 2005;78(2-3):147-56. [DOI: 10.1016/j.schres.2005.06.004] [PMID: ] - DOI - PubMed
    1. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97. [DOI: 10.1016/S0140-6736(08)60486-9] [PMID: ] - DOI - PubMed
    1. Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW, EUFEST Study Group. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. Journal of Clinical Psychopharmacology 2011;31(3):274-80. [DOI: 10.1097/JCP.0b013e3182199bcc] [PMID: ] - DOI - PubMed
Kinon 2004 {published data only}
    1. Kinon BJ, Ahl J, Rotelli MD, McMullen E. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. American Journal of Emergency Medicine 2004;22(3):181-6. [DOI: 10.1016/j.ajem.2004.02.021] - DOI - PubMed
Krakowski 2006 {published data only}
    1. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophrenia Research 2009;110(1-3):95-102. [DOI: 10.1016/j.schres.2009.02.006] - DOI - PubMed
    1. Krakowski M, Czobor P. A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine and haloperidol. International Clinical Psychopharmacology 2011;26:e135-6. [DOI: 10.1097/01.yic.0000405864.74645.87] - DOI - PubMed
    1. Krakowski M, Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophrenia Research 2011;130(1-3):27-33. [DOI: 10.1016/j.schres.2011.04.005] [PMID: ] - DOI - PubMed
    1. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2006;63(6):622-9. [DOI: 10.1001/archpsyc.63.6.622] - DOI - PubMed
    1. Krakowski MI, Czobor P. A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol.. Journal of Clinical Psychopharmacology 2010;30(2):198-200. [DOI: 10.1097/JCP.0b013e3181d47b5e] - DOI - PubMed
Lahti 2007 {published data only}
    1. Bolding MS, White DM, Hadley JA, Weiler M, Holcomb HH, Lahti AC. Antipsychotic drugs alter functional connectivity between the medial frontal cortex, hippocampus, and nucleus accumbens as measured by H215O PET. Frontiers in Psychiatry 2012;3:105. [DOI: 10.3389/fpsyt.2012.00105] [PMID: ] - DOI - PMC - PubMed
    1. Lahti AC, Holcomb HH, Tamminga CA, Weiler MA. Limbic rcbf patterns predict treatment response in schizophrenia. Schizophrenia Bulletin 2007;33(2):474.
    1. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL. Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology 2009;34(13):2675-90. [DOI: 10.1038/npp.2009.94] [PMID: ] - DOI - PMC - PubMed
Li 2005f {published data only}
    1. Li C, Zhu S, Ling Z. A controlled study of olanzapine and haloperidol in the treatment of the acute phase of schizophrenia. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學] 2005;17(5):275-7.
Lieberman (HGDH) 2003 {published data only}7019
    1. Breier A, Keefe RS, Young CA, Purdon SE, Gold JM, Davis KL. A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia. Schizophrenia Research 2003;60:274-5. [CSZG: 9685] [EMBASE 2003496187] - PubMed
    1. Breier AF, Zipursky RB, Perkins DO, Addington JM, Tohen MF, David SR, et al. A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002. [CSZG: 8951] [Lilly study possible stands alone not published]
    1. Centorrino F, Hamer RM, Tohen M, Lieberman JA. Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia. Schizophrenia Research 2003;60:277. [CSZG: 9691] [EMBASE: 2003241517]
    1. Green A, Tohen M, Strakowski SM, Lieberman JA, Glick D, Clarke SW. Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine versus haloperidol. Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada) 2001;1-2 Suppl:230. [CSZG: 6021] [MEDLINE: ]
    1. Green A, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick ICWS, GDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research 2004;66(2-3):125-35. [CSZG: 10111] [PMID 15061244] - PubMed
Lilly (HGGN) 2000 {published data only}
    1. Breier A, Young C, Purdon SE, Gold JM, Davis, KL, Keefe RSE. A one year double-blind comparision of the neurocognitive efficacy of olanzapine, risperidone and haloperidol in patients with schizophrenia. In: Schizophrenia Research March 29 - April 2003; Colorado Springs, CO. 2003.
    1. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A, HGGN Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research 2006;81(1):1-15. [DOI: 10.1016/j.schres.2005.07.038] [PMID: ] - DOI - PubMed
    1. Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry 2009;9(1):44. [DOI: 10.1186/1471-244X-9-44] - DOI - PMC - PubMed
    1. Liu-Seifert H, Osuntokun OO, Godfrey JL, Feldman PD. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Preference and Adherence 2010;4:369-77. [PMID: ] - PMC - PubMed
    1. Lysaker PH. Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks. Evidence-Based Mental Health 2006;9(3):71. [DOI: 10.1136/ebmh.9.3.71] - DOI - PubMed
Lilly (S029) 2007 {published data only}
    1. Eli Lilly. Efficacy study of switching stabilized schizophrenic patients from conventional to atypical antipsychotic treatment. Unpublished report 2007;NA:1-26. [NCT00191555]
Lilly 2006a {published data only}
    1. Adrianzén C, Sánchez M, Córdova J, Castillo I. Olanzapina versus haloperidol: efectividad en la funcionalidad y estado de salud en una muestra de pacientes venezolanos con esquizofrenia. ERTE 2008;9:254-60. [http://www.polemos.com.ar/docs/vertex/vertex81.pdf#page=15] - PubMed
    1. Eli Lilly. Olanzapine for schizophrenia: a cost benefit study. STUDY F1D-GW-S034 2006.
Lin 2008 {published data only}
    1. 林福荣. Comparative efficacy of olanzapine and haloperidol treatment episode psychosis patients [奥氮平与氟哌啶醇治疗首发精神病患者的疗效对比研究]. 中外健康文摘 [医药月刊] 2008;5(4):269-70.
Lindenmayer 2007 {published data only}
    1. Lindenmayer J, Iskander A, Abad T, Parker B, Lerman M, Khan A. A randomized, double-blind study of olanzapine vs haloperidol in the treatment of primary negative symptoms in schizophrenia. Schizophrenia Bulletin 2005;31(2):493-4.
    1. Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry 2007;68(3):368-79. [PMID: PMID: 17388705] - PubMed
Liu 2010l {published data only}
    1. 刘国斌. Effect of olanzapine and haloperidol in the treatment of Schizophrenia [Google Translate] [奥氮平与氟哌啶醇治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(14):1782, 1835.
Liu 2011i {published data only}
    1. 刘晓军. Controlled study of olanzapine and haloperidol in schizophrenia cognitive function [奥氮平与氟哌啶醇对精神分裂症认知功能影响的对照研究]. Journal of Medical Forum [医药论坛杂志] 2011;32(13):126-8.
Liu 2012ao {published data only}
    1. 柳贵明, 叶渊, 张跃坤. Senile controlled study of olanzapine and haloperidol in schizophrenia treatment [Google Translate] [奥氮平与氟哌啶醇治疗老年期精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2012;-(04):396-7.
Luo 2012d {published data only}
    1. 罗思光. 奥氮平与氟哌啶醇治疗首发精神病患者的疗效对比研究. 健康必读（中旬刊） 2012;11(6):35.
Ma 2005d {published data only}
    1. 马兆峰, 陈希, 庄晓华, 张立亮. The efficacy and quality of life of patients with schizophrenia, olanzapine [奥氮平对精神分裂症患者疗效及生活质量的影响]. Chinese Journal of Behavioral Medical Science [中国行为医学科学] 2005;14(8):723-4.
Malyarov 1999 {published data only}5262
    1. Malyarov S, Dzub G. Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol. In: Journal of the European College of Neuropsychopharmacology. 1999:S296. [CSZG: 5971] [MEDLINE: ]
Mousavi 2013 {published data only}
    1. Mousavi SG, Rostami H, Sharbafchi MR, Boroujeni AS, Mahaki B, et al. Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis. Journal of Research in Pharmacy Practice 2013;2(4):138-44. [DOI: 10.4103/2279-042X.128142] [PMID: 24991622] - DOI - PMC - PubMed
Nag 2013 {published data only}
    1. Bhardwaj R, Nag P, Srivastava B, Gaur S, Kaul V. Depressive symptomatology: comparative evaluation of typical versus atypical antipsychotics in schizophrenic patients using MADRS scale. Indian Journal of Applied Research 2016;6(12):47-50. [http://wwjournals.com/index.php/ijar/article/viewFile/1114/1108]
Namjoshi 2002 {published and unpublished data}
    1. Namjoshi M, Young C, Huang L, Edgell ET, Breier A. Conical and quality-of-life outcomes associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from a US random study. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada) 2002;Suppl 1:S127.
    1. Namjoshi M, Young CA, Huang L, Edgell E, Breier A. Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: results from a U.S. randomized controlled trial. In: Schizophrenia Research International Congress on Schizophrenia Research, March 29-April 2, 2003, Colorado Springs, CO. 2003. [EMBASE 2003496187]
    1. Namjoshi M, Young CA, Huang L, Edgell E, Breier A. Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: results from a U.S. randomized controlled trial. Schizophrenia Research 2003;60:296. [N0146099645]
    1. Namjoshi M, Young CM, Huang L, Edgell ET, Breier A. Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial. European Neuropsychopharmacology 2002;(Suppl 3):S315.
Pan 2005 {published data only}
    1. Pan N, Yang X, Mei Q. Large dose of olanzapine in the ictus treatment of agitated symptoms of schizophrenia. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志] 2005;11(2):113-5.
Parabiaghi (GiSAS) 2010 {published and unpublished data}
    1. Parabiaghi A, D'Avanzo B, Tettamanti M, Barbato A, GiSAS Study Group. The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemporary Clinical Trials 2011;32(5):675-84. [DOI: 10.1016/j.cct.2011.04.008] [PMID: ] - DOI - PubMed
    1. Parabiaghi A, Tettamanti M, D'Avanzo B, Barbato A, GISAS Study Group, Aguglia E, et al. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatrica Scandinavica 2016;133(1):63-75. [DOI: 10.1111/acps.12468] [PMID: ] - DOI - PubMed
    1. Parabiaghi A. Aripiprazole, Olanzapine and Haloperidol in the Long-Term Treatment of Schizophrenia: The Rationale and Development of the GiSAS Pragmatic Randomized Controlled Trial, a Consideration and Empirical Study of Factors Associated With Recruitment (the GiSAS Survey) and the Concept of Endpoints Using a Secondary Analysis of Existing Data and a Preliminary Analysis of GiSAS Trial Data [Doctoral dissertation]. The Open University, 2012.
Qi 2013b {published data only}
    1. 齐俊茹. Olanzapine analysis of the effect of treatment of mental illness [Google Translate] [奥氮平治疗精神病的效果分析]. 中外医学研究 2013;NA(16):139.
Qin 2006a {published data only}
    1. Qin Y. A comparative trial of olanzapine versus haloperidol in the treatment of schizophrenia [再普乐与氟哌啶醇治疗精神分裂症的比较研究]. Hebei Medicine [河北医学] 2006;12(10):1011-3.
Raposo 2011 {published data only}
    1. Raposo NRB, Ferreira AS, Gattaz WF. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry 2011;44(5):169-72. [DOI: 10.1055/s-0031-1280793]] - PubMed
Rosenheck (HGFI) 2003 {published data only}7169
    1. Davis L, Sheikh J, Rosenheck R, Frecska E, Douyon R, Evans D, et al. To determine if olanzapine is more cost effective than haloperidol for the treatment of schizophrenia/The clinical and economic impact of olanzapine in the treatment of schizophrenia. National Institutes of Health (http://www.clinicaltrials.gov/) accessed 16 February 2001. [CSZG: 5460]
    1. Glazer WM. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2004;291(9):1064-5. [CSZG: 10079] [PsycINFO 2004-11623-005] - PubMed
    1. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702. [CSZG: 9954] - PubMed
Saddichha 2007 {published data only}
    1. Saddichha S, Akhtar S. Antipsychotic use associated with metabolic & weight changes in schizophrenia. International Clinical Psychopharmacology 2011;26:e134-5. [https://journals.lww.com/intclinpsychopharm/Citation/2011/09001/Antipsyc...]
    1. Saddichha S, Akhtar S. Hypertension, diabetes and cardiometabolic changes associated with antipsychotic use in schizophrenia. International Clinical Psychopharmacology 2011;26:e143. [https://journals.lww.com/intclinpsychopharm/Citation/2011/09001/Hyperten...]
    1. Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Journal of Clinical Psychopharmacology 2008;28(1):27-31. [DOI: 10.1097/jcp.0b013e3181602fe6] - DOI - PubMed
    1. Saddichha S, Manjunatha N, Akhtar S. Obesity, diabetes and hypertension associated with antipsychotic use in drug naive schizophrenia. - 2010;-:-. - PubMed
    1. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia–effect of disease or drug? Results from a randomized, double‐blind, controlled prospective study in first‐episode schizophrenia. Acta Psychiatrica Scandinavica 2008;117(5):342-7. [DOI: 10.1111/j.1600-0447.2008.01158.x] - DOI - PubMed
San 2012 {published data only}
    1. Arranz B, Safont G, Corripio I, Ramirez N, Dueñas RM, Perez V, et al. Substance use in patients with first-episode psychosis: is gender relevant? Journal of Dual Diagnosis 2015;11(3-4):153-60. [DOI: 10.1080/15504263.2015.1113761] [PMID: ] - DOI - PubMed
    1. San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Research 2012;200(2-3):693-701. [DOI: 10.1016/j.psychres.2012.07.005] [PMID: PMID: 22954905] - DOI - PubMed
Sergi 2007 {published data only}
    1. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, et al. Social cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol. American Journal of Psychiatry 2007;164(10):1585-92. [DOI: 10.1176/appi.ajp.2007.06091515] [PMID: ] - DOI - PubMed
Song 2009c {published data only}
    1. 宋燕, 孙燕妮, 伍毅, 宋兵福, 丁华, 郑琰婷. A control study on olanzapine versus haloperidol in the treatment of female schizophrenic [奥氮平与氟哌啶醇治疗女性精神分裂症]. Sichuan Mental Health [四川精神卫生] 2009;22(1):26-9.
Taraskina 2017 {published data only}
    1. Taraskina AE, Nasyrova RF, Zabotina AM, Sosin DN, Sosina КА, Ershov EE, et al. Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines. BMC Psychiatry 2017;17(1):394. [10.1186/s12888-017-1562-1] [PMID: PMID: 29221470] - PMC - PubMed
Tollefson (HGAJ) 1997 {published and unpublished data}14625
    1. Alan B, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia. In: 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:144. [CSZG: 4633] - PubMed
    1. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. Pharmacoeconomics 1998;13(5 Pt 2):575-88. [CSZG: 18839] - PubMed
    1. Andersen S, Cohen L, Goldstein J, Tohen M, Tollefson G. Sex and neuroendocrine differences in response to treatment with olanzapine: a preliminary analysis. Schizophrenia Research 1998;29(1-2):186-7. [CSZG: 7071]
    1. Andersen SW, Tollefson GD, Sanger T. Depressive signs and symptoms in schizophrenia:a prospective blinded trial of olanzapine and haloperidol. In: APA Annual Meeting; May 15-20; Washington DC; USA. 1999. [CSZG: 3446] [CSG NO. 4125] - PubMed
    1. Baker R W, Julier B, Stauffer V. Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo. In: 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001. [CSZG: 7566]
Vedam 2022 {published data only}
    1. Vedam VA, Ghanta MK, Kantipudi SJ, David DC, Vijayalakshmi M, Nuthalapati P. Homocysteine levels and clinical outcomes in schizophrenia—a pilot randomized controlled trial. Journal of Pharmacology and Pharmacotherapeutics 2022;13(3):284-92. [DOI: 10.1177/0976500X2211286] - DOI
Walther 2014 {published data only}
    1. Walther S, Moggi F, Horn H, Moskvitin K, Abderhalden C, Maier N, et al. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. Journal of Clinical Psychopharmacology 2014;34(1):124-8. [DOI: 10.1097/JCP.0000000000000050] - DOI - PubMed
Wang 2012k {published data only}
    1. 汪艳, 蔡丽伟, 张红星, 杜波, 金超, 阎浩, et al. Randomized controlled study of haloperidol and olanzapine in the treatment of schizophrenia efficacy and safety [Google Translate] [氟哌啶醇与奥氮平治疗精神分裂症疗效和安全性的随机对照研究]. Chinese Journal of Nervous and Mental Diseases [Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi; 中国神经精神疾病杂志] 2012;-(04):217-21.
Wang 2013az {published data only}
    1. 王茜, 王洪明. Olanzapine and haloperidol controlled study of patients with refractory schizophrenia affect the quality of life of the [Google Translate] [奥氮平与氟哌啶醇对难治性精神分裂症病人生活质量影响的对照研究]. 中国卫生产业 2013;-(13):26-7.
Xianzhen 2004 {published data only}
    1. Zheng X, Jiang F. A double blind comparing study between the effects of haloperidol and olanzapine on the quality of life of the patients with schizophrenia [奧氮平與氟哌啶醇對精神分裂癥病人生活質量影響的雙盲對照研究]. Journal of Jining Medical College 2004;27(3):20-2.
Xu 2014n {published data only}
    1. 许素娥. 奥氮平与氟哌啶醇对精神分裂症患者生活质量影响的对照研究. 中外健康文摘 2014;-(18):107-8.
Zhang 2005g {published data only}
    1. Zhang M-L, Yuan G-Z, Yao J-J, Chu X, Zhang Y-B, Zhou D-X, et al. Changes in the serum levels of prolactin and growth hormone in patients with schizophrenic after different drug administration [不同藥物治療精神分裂癥患者血清催乳素與生長激素水平的變化]. Chinese Journal of Clinical Rehabilitation 2005;9(32):76-7.
Zhang 2010ad {published data only}
    1. 张树龙. Olanzapine control study of first episode schizophrenia [Google Translate] [奥氮平治疗首发精神分裂症对照研究 []. China Contemporary Medicine [当代医学] 2010;16(12):141-2.
Zhang 2010ae {published data only}
    1. 张海燕. Tablets of olanzapine treatment of schizophrenia and the effect of haloperidol compared SBR [Google Translate] [奥氮平片与氟哌丁苯治疗精神分裂症疗效比较 []. Chinese Journal of Modern Drug Application [中国现代药物应用] 2010;4(8):133.
Zhang 2013m {published data only}
    1. 张懿. Olanzapine and haloperidol in the treatment of schizophrenia comparison of efficacy [Google Translate] [奥氮平与氟哌啶醇治疗精神分裂症疗效比较]. Medical Journal of Chinese People's Health [中国民康医学] 2013;-(16):47+67.
Zhang 2016al {published data only}
    1. 张建, 常余善, 蒋正伟. 氟哌啶醇与奥氮平治疗精神分裂症的临床疗效对比研究. 临床合理用药杂志 2016;9(21):11-3.
Zheng 2003b {published data only}
    1. Zheng R. Olanzapine treatment of positive symptoms of schizophrenia and ammonia piperidinol control study [奥氮平与氨哌啶醇治疗精神分裂症阳性症状的对照研究]. Acta Academiae Medicinae Suzhou [苏州医学院学报] 2003;23(2):218-9.
Zhu 2014f {published data only}
    1. 朱虹, 贾竑晓, 何瑞荣, 卜力, 张燕敏, 许英. 奥氮平对精神分裂症患者认知功能和生活质量改善作用及疗效. China Journal of Health Psychology [中国健康心理学杂志] 2014;22(10):1451-3.
Zubair 2020 {published data only}
    1. Zubair UB, Ali SA, Taj R, Batool SM. Comparison of effectiveness of antipsychotics in schizophrenia: second-generation versus the first-generation. Journal of Ayub Medical College Abbottabad 2020;32(1):24-7. [PMID: PMID: 32468749] - PubMed

References to studies excluded from this review

Addington 1998 {published data only}
    1. Addington DE, Addington JM. Costs of novel antipsychotics in clinical practice. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Allan 1998 {published data only}
    1. Allan ER, Sison CE, Alpert M, Connolly B, Crichton J. The relationship between negative symptoms of schizophrenia with extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacology Bulletin 1998;34(1):71. - PubMed
Allison 1998 {published data only}
    1. Allison DB, Mentor JL, Heo M, Weiden PJ, Chandler LP, Cappelleri J. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
    1. Allison DB, Mentor JL, Heo M, Weiden PJ, Chandler LP, Cappelleri J. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. In: Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998. 1998. [American J of Psychiatry 1999 vol 156, p1686-96]
Alvarez 2005 {published data only}
    1. Alvarez M, Gonzalez-Blanch C, Perez-Iglesias R, Perez-Pardal, T, Martinez-Garcia O, Crespo-Facorro B, et al. Early intervention in antipsychotic-induced weight gain in first episode psychosis. International Congress on Schizophrenia Research 2005;31(2):518.
    1. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martínez-García O, Perez-Pardal T, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial.. Journal of Clinical Psychiatry 2006;67(8):1253-60. [DOI: 10.4088/jcp.v67n0812] - DOI - PubMed
    1. Álvarez-Jiménez M, Martínez-García O, Pérez-Iglesias R, Ramírez ML, Vázquez-Barquero JL, Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophrenia Research 2010;116(1):16-9. [DOI: 10.1016/j.schres.2009.10.012] - DOI - PubMed
Apicella 2001 {published data only}
    1. Apicella A. National Alliance for Research on Schizophrenia and Depression. www.mhsource.com/narsad/bd/studyops.html 2001.
Apiquian 2003 {published data only}
    1. Apiquian R, Fresan A, Errera K, Ulloa RE, Loyzaga C, De LaFuente-Sandoval C, et al. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. International Journal of Neuropsychopharmacology 2003;6(4):403-8. [EMBASE: 2004054013] - PubMed
Aquila 2000 (HGEC) {published data only}
    1. Aquila R, Weiden PJ, Kinon BJ, Milton DR, Zygmunt A, Swindle RW, et al. Effectiveness of olanzapine upon psychiatric and vocational rehabilitation outcomes. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.
Arango 2001 {published data only}
    1. Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on auditory sensory gating in schizophrenia. American Journal of Psychiatry 2003;160(11):2066-8. [PMID 14594761] - PubMed
    1. Arango C, Summerfelt AT, Buchanan RW. Lack of P50 changes in a randomized double blind study of olanzapine and haloperidol. Schizophrenia Research 2001;49(1-2 Suppl):197. [MEDLINE: ]
Arous 2016 {published data only}
    1. Arous A, Chebbi W, Mrizak J, Ammar HB, El Hechmi Z. Effects of atypical and conventional antipsychotics on cognition in schizophrenia. European Neuropsychopharmacology 2016;2(26):S347-8.
Awad 2002b {published data only}
    1. Awad AG, Vourganti L, Dugar A. Patient attitude after switch to ziprasidone from other antipsychotics. European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden) 2002;17(Suppl 1):102s. [probably Pfizzer study]
Baker 2003 {published data only}
    1. Baker R, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. Schizophrenia Research 2003;60:272. [EMBASE 2003496187]
    1. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. Journal of Clinical Psychopharmacology 2003;23(4):342-8. [PMID 12920409] - PubMed
Baldacara 2011 {published data only}
    1. Baldaçara L, Sanches M, Cordeiro DC, Jackowski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Brazilian Journal of Psychiatry 2011;33(1):30-9. [DOI: 10.1590/S1516-44462011000100008] - DOI - PubMed
Barak 2005 {published data only}
    1. Barak Y, Swartz M, Plopsky I. Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients. International Clinical Psychopharmacology 2005;20(6):315-7. [PMID: ] - PubMed
Bayar 2005 {published data only}
    1. Bayar R, Kocabasoglu N, Yargic I, Sevim ME, Corapcioglu A, Benbir G. A multi-centered study evaluating the effects of haloperidol and olanzapine on depressive symptoms in schizophrenic patients.. European Neuropsychopharmacology 2005;15:S474.
Beasley 1996c {published data only}
    1. Beasley C, Tollefson G, Wood G, Tran P, Satterlee W, Beuzen J. Safety overview of olanzapine. In: Xth World Congress of Psychiatry. Madrid, Spain; August 23-28, 1996. 1996.
Beasley 2003 (HGGI) {published data only}
    1. Beasley CM, Hamilton SH, Dossenbach M. Relapse prevention with olanzapine. Schizophrenia Research 2000;41(1):196-7. [CSG NO. 4512]
    1. Beasley CM, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology 2003;23(6):582-94. [MEDLINE: ] - PubMed
    1. Beasley Jr C, Hamilton S, Dossenbach M. Relapse prevention with olanzapine. Journal of the European College of Neuropsychopharmacology 2000;10(Suppl 3):S304.
Beuzen 1996 (HGCE) {published data only}
    1. Beuzen JN. Olanzapine - cognitive and motor effects in healthy elderly. In: Xth World Congress of Psychiatry. Madrid, Spain; August 23-28, 1996. 1996.
    1. Taylor N, Beuzen JN, Wesnes K, Wood A. The effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers. Schizophrenia Research 1996;18(2-3):VC2. - PubMed
Birkett 1994 {published data only}
    1. Birkett P. State of the Art - Winter Workshop on Schizophrenia, Les Diablerets, Switzerland, January 1994. Journal of Psychopharmacology 1995;9(2):157-60. - PubMed
Bourin 2007 {published data only}
    1. Barbato LM, Newcomer JW, Heisterberg J. Efficacy and metabolic profile of bifeprunox in patients with schizophrenia. Schizophrenia Bulletin 2007;33(2):419.
    1. Bourin M, Debelle M, Heisterberg J, Josiassen MK, Ostergaard JB, Sands E. 304–Efficacy of bifeprunox in patients in the post-acute, maintenance phase of schizophrenia: Findings from a 6-month study. Schizophrenia Research 2008;98:158. [DOI: 10.1016/j.schres.2007.12.371] - DOI
    1. Bourin M, Debelle M, Heisterberg J, Krog Josiassen M, Buch Ostergaard J, Sands EA, et al. Long-term efficacy and safety of bifeprunox in stable patients with schizophrenia: findings from a 6-month study. Journal of the European College of Neuropsychopharmacology 2007;17(4):S454.
    1. Ostergard JB, Barbato LM, Yeung PP. Bifeprunox is safe and effective in preventing deterioration in patients with stable schizophrenia: results from a 6-month, placebo-controlled study. Schizophrenia Bulletin 2007;33(2):422-3.
    1. Shapira NA, Newcomer JW, Barbato LM, Heisterberg J, Yeung P. Metabolic effects of bifeprunox in patients with schizophrenia. Schizophrenia Bulletin 2007;33(2):459.
Britto 2002 {published data only}
    1. Britto D. Ziprasidone quality of life study in the treatment of chronic schizophrenia. National Research Register 2002;1. [N0083099522]
Buchsbaum 2004 {published data only}
    1. Buchsbaum MS, Haznedar MM, Aronowitz J, Brickman AM, Newmark RE, Bloom, et al. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophrenia Research 2007;94(1-3):293-305. [DOI: 10.1016/j.schres.2007.04.027] - DOI - PubMed
    1. Buchsbaum MS, Haznedar MM, Aronowitz J, Brickman AM, Newmark RE, Canfield E, et al. White matter volume and anisotropy in never medicated psychotic adolescents treated with olanzapine and haloperidol. Journal of the European College of Neuropsychopharmacology 2004;17(4):S426.
    1. Buchsbaum MS, Haznedar MM, Hazlett E. Antipsychotic response prediction with FDG-PET in schizophrenia. World Psychiatry 2004;3:S1:148.
Burgoyne 1996 {published data only}
    1. Burgoyne K, Ananth J, Gadasally R, Smith M. Maintenance treatment with olanzapine for schizophrenic patients. In: Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998. 1998.
    1. Burgoyne K, Ananth J, Smith M, Swartz JR, Gadasally R, Arns P. Olanzapine versus haloperidol: the results of a double-blind study on acute psychotic patients. In: XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia; June 23-27, 1996. 1996.
Castilla 2002 {published data only}
    1. Castilla R. Early medication intervention in the treatment of psychosis in children. In: International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada). 2002:S51.
Chetvertnykh 2008 {published data only}
    1. Chetvertnykh I, Soulimov GY, Mosolov SN. Longterm efficacy and safety of atypical antipsychotics and haloperidol in neuroleptic naive psychotic patients. International Journal of Neuropsychopharmacology 2008;11:139.
Clouth 1999 {published data only}
    1. Clouth J. Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol. In: APA Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG NO. 4109]
Corya 2002 (HGGA) {published data only}
    1. Corya S, Dubé S, Andersen SW, Sanger TM, Clemow D, Tohen M, et al. Olanzapine-fluoxetine combination for psychotic major depression. In: International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada). 2002:S144. [lilly data]
Cutler 2002 {published data only}
    1. Cutler NR, Simpson G, Weiden PJ, Romanoa SJ. Effects of oral ziprasidone on weight and serum lipids in patients with schizophrenia. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;3 Suppl 1:160.
Dalheim 1997 {published data only}
    1. Dalheim LJ, Weiden PJ, Aquila R, Standard J, Emanuel M, Zygmunt A. Olanzapine crossover in stable outpatients. In: American Psychiatric Association, 150th Annual Meeting, San Diego, CA, USA. 1997.
Daskalakis 2003 {published data only}
    1. Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S. The effects of antipsychotics on cortical inhibition using transcranial magnetic stimulation. Schizophrenia Research 2003;1(60):249. [DOI: 10.1016/S0920-9964(03)81269-0] - DOI - PubMed
Davis 1998 {published data only}
    1. Davis JM, Janicak PG, Sharma RP, Manav R. Comparisons of the effects of the newer atypical antipsychotics in the treatment of schizophrenia: a meta-analysis. In: 151st Annual Meeting of American Psychiatric Association. May 30-June 4, Toronto, ON, Canada. 1998. [now published - independent data not lilly]
    1. Davis JM, Sharma RP, Manav R. Comparisons of the effects of the newer atypical antipsychotics in the treatment of schizophrenia: a meta-analysis. In: 151st Annual Meeting of American Psychiatric Association. May 30-June 4, Toronto, ON, Canada. 1998.
Devanand 1998 {published data only}
    1. Devanand DP, Michaels K, Sackeim HA, Marder K, Mayeux RP. Antipsychotics in the treatment of dementia complicated by psychosis. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada. May 30-June 4, 1998.
    1. Devanand DP. Classic neuroleptics in dementia. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Docherty 2002 {published data only}
    1. Docherty JP, Napolitano J, Mahmoud RA, Martinez RA, Lasser RA, Pandina GJ, et al. Anticholinergic effect of atypical antipsychotics in elderly patients. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
    1. Tune L, Mulsant B, Gharabawi G. Anticholinergic effect of atypical antipsychotics in elderly patients. European Neuropsychopharmacology 2002;12(Suppl 3):S314.
Dolnak 2000 {published data only}
    1. Dolnak DR, Hyman Rapaport M, Caligiuri M, Lohr J, Golshan S. A prospective, randomized, double-blind study contrasting motor dysfunction, negative symptoms and functioning in schizophrenic patients treated with olanzapine and risperidone.. In: 40th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2000 May 30 - Jun 2; Boca Raton, Florida, USA. 2000:133.
    1. Dolnak DR, Minn K, Wieneke M, Watson, Espinoza S. Olanzapine versus haloperidol in the treatment of schizophrenia. In: American Psychiatric Association, 149th Annual Meeting; May 4-9, 1996. 1996.
    1. Dolnak DR, Rapaport MH, Michael C, Shahrokh G. Motor dysfunction in schizophrenia. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.
    1. Dolnak DR, Rapaport MH, Michael C, Shahrokh G. Motor dysfunction in schizophrenia. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
    1. Dolnak R, Rapaport MH. A prospective, randomized, doubleblind study examining functioning in schizophrenic patients treated with olanzapine and risperidone. In: Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada). 2001:225-6. [MEDLINE: ]
Dossenbach 1997 {published data only}
    1. Dossenbach M, Friedel P, Folnegovic V, Jackovljevic M, Hutujac L, Uglesic B, et al. Olanzapine vs. fluphenazine - 6 weeks treatment of acute schizophrenia. In: 10th European Colleague of Neuropsychopharmacology Congress 1997 September 13-17 Vienna. 1997.
Erinfolami 2009 {published data only}
    1. Erinfolami A, Ola B, Olagunju A. Impact of atypical and conventional antipsychotics on the quality of life of patients with schizophrenia: a preliminary report from Lagos teaching hospitals. unknown source 2009;-:125.
Esel 2001 {published and unpublished data}5709
    1. Esel E, Basturk M, Saffet Gonul A, Kula M, Tayfun Turan M, Yabanoglu I, et al. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology 2001;26(6):641-7. [CSZG: 7677] [MEDLINE: ] - PubMed
Fallahi 2011 {published data only}IRCT138706051100N1
    1. Fallahi B, Beiki D. Evaluation of therapeutic efficacy of treatment with olanzapine and halopridol on regional cerebral blood flow measured by SPECT in patients with schizophrenia, correlating with the response to treatment. Study protocol 2011;NA:0-3.
Finzen 2002 {published data only}
    1. Finzen A. Changing neuroleptics: from new to conventional - and vice versa [Neuroleptikawechsel: von atypischen zu konventionellen und zuruck - und - umgekehrt]. Psychiatrische Praxis 2002;29(8):445-6.
Fleming 1999 {published data only}
    1. Fleming K, Potkin SG, Alva G, Carreon D. Dissociation of improvement in neurocognition and negative symptomatology with olanzapine and clozapine conference abstract. In: Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA). 1999:279.
Freeman 2009 {published data only}
    1. Freeman DJ, DiPaula BA, Love RC. Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost‐minimization study. Pharmacotherapy: the Journal of Human Pharmacology and Drug Therapy 2009;29(8):930-6. [DOI: 10.1592/phco.29.8.930] [PMID: ] - DOI - PubMed
Gallinat 2001 {published data only}
    1. Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R, et al. P300 and symptom improvement in schizophrenia. Psychopharmacology 2001;158(1):55-65. [MEDLINE: ] - PubMed
Goldman 2004 {published data only}
    1. Goldman MB, Hussain N. Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study. Journal of Clinical Psychopharmacology 2004;24(6):678-80. [DOI: 10.1097/01.jcp.0000145337.07676.2f] - DOI - PubMed
Gothelf 2003 {published data only}
    1. Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal GKL, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. Journal of Neural Transmission 2003;110(5):545-60. [MEDLINE: ] [PMID 12721815] - PubMed
Grecu 2006 {published data only}
    1. Gabos Grecu I, Gabos Grecu M, Pop M. Clinical effectiveness of atypical vs typical antipsychotics in treatment of schizophrenic patients. unknown 2006;-:-.
Harrigan 2004 {published data only}
    1. Chiu CC, Chang WH, Huang MC, Chiu YW, Lane HY. Regular-dose risperidone on QTc intervals. Journal of Clinical Psychopharmacology 2005;25(4):391-3. [DOI: 10.1097/01.jcp.0000170032.78060.cd] - DOI - PubMed
    1. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 2004;24(1):62-9. [DOI: 10.1097/01.jcp.0000104913.75206.62] [PMID: ] - DOI - PubMed
Hazlett 2009 {published data only}
    1. Hazlett E. Predicting best treatment response in schizophrenia with striatal function. NA 2009;-:-.
    1. Haznedar MM. Prediction of antipsychotic response with diffusion tensor imaging. unknown -;-:-.
Hrdlicka 2001 {published data only}
    1. Hrdlicka M, Rosillon D, Duchesne I. Czech results of the RODOS study: comparison of risperidone and olanzapine from the point of view of efficacy, tolerability and treatment costs [Ceske vysledky studie RODOS: Porovnani risperidonu a olanzapinu z hlediska ucinnosti, snasenlivosti a nakladu lecby]. Ceska A Slovenska Psychiatrie 2001;97(7):343-9. [should be 3 publications Janssen data]
Hsu 2010 {published data only}
    1. Hsu WY, Huang SS, Lee BS, Chiu NY. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. Journal of Clinical Psychopharmacology 2010;30(3):230-4. [DOI: 10.1097/JCP.0b013e3181db8715] [PMID: ] - DOI - PubMed
Irwin 2003 {published data only}
    1. Irwin J, Moses SN, Edgar JC, Torres F, Thoma RJ, Hanlon FM, et al. Olanzapine and risperidone in schizophrenia: a randomized double-blind crossover study. In: Schizophrenia Research. Vol. 60. 2003:286. [EMBASE: 2003241517]
Jarboe 2001 {published data only}
    1. Jarboe KS, Lewine RR. Haloperidol versus olanzapine induced weight gain and clinical relevance, a double-blind and open label comparison. Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada) 2001;1-2 Suppl:232. [MEDLINE: ]
Javitt 2001 {published data only}
    1. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2001;4(4):385-91. [MEDLINE: ] - PubMed
Jerrell 2002 {published data only}
    1. Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophrenia Bulletin 2002;28(4):589-605. [EMBASE 2003196530] - PubMed
Kalali 2000 {published data only}
    1. Kalali A, Lasser R, Campbell B, Cucchiaro J, El-Bizri H, Guven A, et al. The management of cultural differences and the importance of safety monitoring in global studies: the realize clinical program. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico. 2000.
Kasthurip 2012 {published data only}
    1. Kasthurip. A comparative study of efficacy and safety of olanzapine versus haloperidol in schizophrenia in a tertiary care hospital.. Indian Journal of Psychiatry 2012;54:S51.
Kinon (HGFW) {published data only}
    1. Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. In: 40th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2000 May 30 - Jun 2; Boca Raton, Florida. 2000. [N0146103028]
    1. Kinon BJ, Basson B, Wang J, Malcolm SK. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Schizophrenia Research 2000;41(1):194-5. [CSG NO. 4510]
    1. Kinon BJ, Basson BR, Malcolm SK, Breier A. Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine. In: World Congress of Psychiatry (WPA). Hamburg, Germany; August 8-11, 1999. 1999.
    1. Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine. In: 2nd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists. Lake Tahoe, NV, USA; March 25-28, 1999. 1999.
    1. Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine. In: American College of Neuropsychopharmacology (ACNP). Las Carabas, Puerto Rico; December 14-18, 1998. 1998.
Kinon 2003 {published data only}
    1. Ahl J. Olanzapine reduces neuroleptic-induced hyperprolactinemia in schizophrenia. Schizophrenia Research 2003;60:350. [EMBASE: 2003241517]
    1. Kinon BJ, Liu H, Ahl J, Baker RW. Longitudinal effects of olanzapine on fasting serum lipids: a randomized, prospective, four- month study. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[NR553]]
    1. Kinon BJ, Liu H, Ahl J. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[NR552]] - PubMed
    1. Kinon BJ, Milton DR, Hill AL, Williamson DJ. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. Journal of Psychopharmacology 2000;14(3):A60. [N0146103028]
Knegtering 2000 {published data only}
    1. Knegtering R, Boks M, Wiersma D, Blijd C, Bruggeman R, Oer RBV. Sexual dysfunctions in patients on antipsychotics. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
    1. Knegtering R, Boks M, Wiersma D, Blijd C, Bruggeman R, Oer RB. Sexual dysfunctions in patients on antipsychotics. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.
    1. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology 2004;24(1):56-61. [EMBASE: 2004050225] - PubMed
Kolff 2000 {published data only}
    1. Kolff M, Coenen A, Dis H, Duigemans P. Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia. Journal of the European College of Neuropsychopharmacology 2000;Suppl 2:S59.
Kong 2009 {published data only}
    1. Kong BG, Shim JC, Lee SK. Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis. unknown -;-:S525.
Krakowski 2021 {published data only}
    1. Krakowski M, Tural U, Czobor P. The importance of conduct disorder in the treatment of violence in schizophrenia: efficacy of clozapine compared with olanzapine and haloperidol. American Journal of Psychiatry 2021;178(3):266-74. [DOI: 10.1176/appi.ajp.2020.20010052] - DOI - PubMed
Kucerova 2002 {published data only}
    1. Kucerova H. Olanzapine and improvement of tardive dyskinesia. European Psychiatry 2002;17(7):421-4. - PubMed
Lahti 1999a {published data only}
    1. Lahti AC, Holcomb HH, Weiler MA, Parwani A, Michaelidis T, Medoff DR, et al. Changes rcbf after acute challenge with haloperidol and olanzapine in patients with schizophrenia. In: Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA). 1999:224. [MEDLINE: ]
    1. Lahti AC, Weiler MA, Holcomb HH, Lee SM, Tamminga CA. Time course of RCBF changes with haloperidol and olanzapine over a six week treatment. Schizophrenia Research 2003;-:-.
Lilly (HGBM) 1999 {unpublished data only}
    1. Eli Lilly. Open-label clinical trial on antipsychotic efficacy and safety of olanzapine in schizophrenic patients with positive or negative symptomatology. Data supplied to the Cochrane Schizophrenia Group 1999.
Lilly (HGCL) 1999 {unpublished data only}
    1. Eli Lilly. Efficacy and safety of olanzapine in the treatment of schizophrenic, schizophreniform and schizoaffective patients in Saudi Arabia. Data supplied to the Cochrane Schizophrenia Group 1999.
Lilly (HGCV) 1999 {unpublished data only}
    1. Eli Lilly. Olanzapine in schizophrenic patients intolerant of, or resistant to, clozapine. Data supplied to the Cochrane Schizophrenia Group 1999.
Lilly (HGDU) 1999 {unpublished data only}
    1. Eli Lilly. Safety and efficacy of olanzapine in patients with severe haloperidol side effects in Romania. Data supplied to the Cochrane Schizophrenia Group 1999.
Lilly (HGDZ) 1999 {unpublished data only}
    1. Eli Lilly. Efficacy and safety of olanzapine in the treatment of schizophrenic and schizoaffective patients in Russia. Data supplied to the Cochrane Schizophrenia Group 1999.
Lilly (HGEP) 1999 {unpublished data only}
    1. Eli Lilly. Open-label olanzapine. Data supplied to the Cochrane Schizophrenia Group 1999.
Lilly (HGFM) 1999 {unpublished data only}
    1. Eli Lilly. Efficacy and safety of olanzapine in the treatment of schizophrenic patients in China. In: Data supplied to the Cochrane Schizophrenia Group. 1999.
Lilly (HGHB) 2005 {published data only}
    1. Battaglia J, David SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of IM olanzapine in agitated patients. Schizophrenia Research 2002;53(3):182-3. - PubMed
    1. Battaglia J, Houston JP, Ahl J, Meyers AL, Kaiser CJ. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clinical Therapeutics 2005;27(10):1612-8. - PubMed
    1. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine 2003;21(3):192-8. - PubMed
    1. David SR, Battaglia J, Alaka KL, Meehan K, Wright P. Calming versus sedative effects of IM olanzapine in agitated patients. European Psychiatry 2002;17:104-5.
    1. David SR, Beasley CM, Alaka K. QTc intervals during treatment with IM olanzapine in acutely agitated patients. Biological Psychiatry 2002;51(8):78S.
Lilly (HGHV) 2005 {published data only}
    1. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry 2002;59(5):441-8. - PubMed
    1. Breier A, Wright P, Birkett M, David S, Brook S, Meehan K. A double-blind dose response study comparing intramuscular (IM) olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients. Biological Psychiatry 2001;49(8):21S.
    1. Breier A, Wright P, Birkett M, Meehan K, David SR, Brook S. Intramuscular olanzapine: dose-related improvement in acutely agitated patients with schizophrenia. Proceedings of the 154th Annual Meeting of the American Psychiatric Association 2001;5:77.
    1. Smith RC. 10 mg intramuscular olanzapine reduces acute agitation in schizophrenia more effectively than lower doses. Evidence-Based Mental Health 2003;6(1):-. - PubMed
    1. Wright P, Birkett MA, Meehan K, David SR, Brook S, Breier A. A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Schizophrenia Research 2001;49(1-2):250-1.
Lilly (TW‐S025) 2006 {published data only}
    1. Chan HY, Ree SC, Su LW, Chen JJ, Chou SY, Chen CK, et al. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. Journal of Clinical Psychopharmacology 2006;34(3):355-8. - PubMed
    1. Lilly. Clinical Study Summary: F1D-TW-S025. Unpublished data 2006;NA:1-22.
Lima 2003 (HGHS) {published and unpublished data}6937
    1. Lima MS, Mari JJ, Costa AMN, Alexandrini N, Filho SR, Oliverira IR, et al. Quality of life of patients with schizophrenia: a randomised, naturalistic, controlled trial comparing olanzapine with typical antipsychotics in Brazil. Eli Lilly and Company.
    1. Lima MS, Jesus Mari J, Costa AMN, Alexandrini N, Filho SR, Oliveira IR, et al. Quality of life of patients with schizophrenia: a randomized, naturalistic, controlled trial comparing olanzapine with typical antipsychotics in Brazil. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [CSZG: 9416] [N0146103028]
    1. Mari JD, Lima MS, Costa AN, Alexandrini N, Filho SR, Oliveira IR. A nine month naturalistic randomized controlled trial comparing olanzapine and conventional antipsychotics for schizophrenia and related disorders. Schizophrenia Research 2003;60:294. [CSZG: 9720] [EMBASE: 2003241517]
    1. Mari JdJ, Lima MS, Costa AMN, Alexandrini N, Filho SR, Oliveira IR. Olanzapine versus conventional antipsychotics: long-term risk of tardive dyskinesia. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [CSZG: 9800] [[NR254]]
Lindenmayer 1998 {published data only}
    1. Lindenmayer JP. Beyond symptoms: optimizing real-world outcomes. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Lindenmayer 2001 {published data only}
    1. Lindenmayer JP, Smith RC, Singh A, Parker B, Chou E, Kotsaftis A. Hyperglycemia in patients with schizophrenia who are treated with olanzapine. Journal of Clinical Psychopharmacology 2001;21(3):351-3. - PubMed
Loza 2001 {published data only}
    1. Loza B, Kucharska-Pietura K, Debowska G. Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores. In: European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey). 2001:285.
    1. Loza B. Atypical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on syllabic and language-related dichotic listening scores. European Neuropsychopharmacology 2002;Suppl 3:S298.
Lu 2022 {published data only}
    1. Lu Z, Zhang Y, Yan H, Su Y, Guo L, Liao Y, et al. ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study. Translational Psychiatry 2022;12(1):56. [DOI: 10.1038/s41398-022-01825-0] - DOI - PMC - PubMed
Mahmoud 1999 {published data only}
    1. Mahmoud RA, Engelhart LM, Janagap C, Awad G. Assessment of symptoms affecting quality of life and patient satisfaction with antipsychotic drugs:new insights for a trial of risperidone/olanzapine. In: APA Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG NO. 4121]
    1. Mahmoud RA, Engelhart LM, Janagap C, Dogherty J. Symptoms commonly attributed to prolactin:a new assessment tool and findings from a trial of risperidone versus olanzapine. In: APA Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG NO. 4122]
Marder 1998 {published data only}
    1. Marder SR. Newer antipsychotics: side-effect profiles. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada. May 30-June 4, 1998.
Maurer 2002 {published data only}
    1. Czekalla J, Volz HP, Maurer I, Smesny S, Sauer H, Dittmann RW, et al. Olanzapine versus haloperidol: a randomized, double-blind cross over study with P-31-nuclear magnetic resonance spectroscopy (MRS) and regional cerebral blood flow measurements (fMRI) of the dorsolateral prefrontal cortex (DLPFC) in schizophrenics. Schizophrenia Research 2002;53(3):180.
    1. Maurer I, Volz HP, Czekalla J, Holstein W, Streck S, Winnefel K. Reduction of arachidonic acid levels by haloperidol treatment in patients with schizophrenia. Schizophrenia Research 2002;53(3):209.
Mauri 2002 {published data only}
    1. Mauri MC, Steinhilber CPC, Laini V, Pavone F, Barale F. Olanzapine and quetiapine in the treatment of acute schizophrenia: a descriptive analysis. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada) 2002;Suppl 1:S119.
McCue 2006 {published data only}
    1. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry 2006;189(5):433-40. [10.1192/bjp.bp.105.019307] - PubMed
    1. Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-Based Mental Health 2007;10(3):76. [http://ebmh.bmj.com/cgi/content/full/10/3/76] - PubMed
McElroy 1998 {published data only}
    1. McElroy SL. Atypical antipsychotics in women with bipolar and other psychiatric disorders. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
McGurk 1998 {published data only}
    1. McGurk SR, Meltzer HY. The affects of atypical antipsychotic drugs on cognitive functioning in schizophrenia. Schizophrenia Research 1998;29(1-2):160.
    1. McGurk SR. The effects of atypical antipsychotic drugs on cognitive function in schizophrenia. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Meltzer 2003 {published data only}
    1. Meltzer HY, Sumiyoshi T, Carpenter WT, Gold JM. Atypical antipsychotic drugs improve cognition in schizophrenia. Biological Psychiatry 2003;51(3):265-8. - PubMed
Mintzer 1998 {published data only}
    1. Mintzer JE. Efficacy and safety of atypical neuroleptics in dementia. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Mitchell 2003 {published data only}
    1. Mitchell M, Earley W, Bari MA, Riesenberg RA, Marquez E, Kurtz D, et al. A preliminary study of the pharmacokinetics and tolerability of higher dose oral olanzapine (20, 30, or 40mg/day) in stable patients with serious mental disorders. Journal of the European College of Neuropsychopharmacology 2003;13(4):S315. [P.2.081]
Mosolov 1998 {published data only}
    1. Mosolov SN. Biological treatment of mental disorders in Russia. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Mulqueen 2000 {published data only}
    1. Mulqueen AW, Wudarsky M, Nicolson RJ, Gochman P, Hamburger S, Lenane M, et al. Weight gain in pediatric patients on typical and atypical antipsychotics. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.
    1. Mulqueen AW, Wudarsky M, Nicolson RJ, Gochman P, Hamburger S, Lenane M, et al. Weight gain in pediatric patients on typical and atypical antipsychotics. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
Naber 1997 {published data only}
    1. Naber D. Evidence of efficacy of neuroleptics in effective versus negative symptoms. In: 10th European College of Neuropsychopharmacology Congress. Vienna, Austria; September 13-17, 1997. 1997.
Narendran 2003 {published data only}
    1. Narendran R, Young CM, Pristach CA, Pato MT, Valenti AM, Fass AR. Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: A pilot study. Journal of Clinical Psychopharmacology 2003;23(1):103-4. - PubMed
NCT00419653 {published data only}
    1. Schlöss R. Modulation of regional brain activation in schizophrenic patients by pharmacological therapy. Study protocol 2007;NA:1-3.
Oliemeulen 2000 {published data only}
    1. Oliemeulen EAP, Jogems-Kosterman BJM, Hoof JJM. Is olanzapine a substitute for clozapine? In: Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA). 1999:146-7. [MEDLINE: ]
    1. Oliemeulen EAP, Hoof JJM, Jogem-Kosterman BJM, Hulsttijn W, Tuynman-Qua HG. Is olanzapine a substitute for clozapine? The effects on psychomotor performance. Schizophrenia Research 2000;41(1):187. [CSG NO. 4502]
Ortega‐Solo (HGBS) {published data only}
    1. Nicolini H, Cruz C, Camarena B, Ortega H. 5HT2A and DRD4 molecular genotypes in a clinical trial of olanzapine versus risperidone in schizophrenic patients. European College of Neuropsychopharmacology, congress, Vienna, Austria, September 13-17 1997.
    1. Ortega-Solo HA, Apiquian R, Ullca RE, Loyzaga C, Mendiazabal A, Brunner E. Olanzapine versus risperidone a double blind trial in Mexican patients. In: Regional meeting of the Collegium Internationale Neuro-Psychopharmacologicum and the Collegio Mexicano de Neuropsicofarmacologia. Acapulco, Mexico; August 21-23, 1997. 1997.
Ortho‐McNeil 2010 {published data only}
    1. A twelve month, prospective, randomized, active controlled, open label, flexible dose study of paliperidone palmitate compared with oral antipsychotic treatment in adults with schizophrenia who have been recently discharged from an inpatient psychiatric hospital. Study protocol 2010.
Paquet 2001 {published data only}
    1. Paquet F, Soucy J, Stip E, Elie A, Cheneval E, Bedard M. Comparaison between olanzapine and haloperidol on the procedural learning and on the striatal D2 receptor occupancy in schizophrenia. Schizophrenia Research 2001;49(1-2):117-8. - PubMed
Parellada 1999 {published data only}
    1. Parellada E, Lomena F, Catafau A, Font M, Gomez JC, Salamero M, Bernardo M. Olanzapine versus haloperidol d2 occupancy:a single photon emission tomography study. In: APA Annual Meeting, May 15-20, 1999, Washington, DC. 1999. [CSG NO. 3999]
Patel 2022 {published data only}
    1. Patel R, Griffiths K, Martinez-Gutierrez A, Garcia-Marin L. Antipsychotic treatment patterns in patients with schizophrenia: A real-world data analysis of electronic health records. Journal of Managed Care: Specialty Pharmacy Supplement Poster Abstracts 2022;28(10-a):54-5.
Perez 2003 {published data only}
    1. Perez R, Gonzalez-Blanch C, Sierra-Biddle D, Marti I, Vazquez-Barquero JL, Crespo-Facorro B. Efficacy and safety of olanzapine, risperidone and haloperidol in acute treatment of patients with first episode psychosis. Schizophrenia Research 2003;1(60):298-9.
Perro 1999 {published data only}
    1. Lambert M, Moritz S, Karow A, Krausz M, Naber D. Quality of life in the treatment of schizophrenia- a randomised, open label comparison trial of amisulpride, olanzapine, quetiapine, risperidone and zotepine. In: Schizophrenia Research (Abstract of the 11th Biannual Winter Workshop on Schizophrenia). 2002.
    1. Perro C LMMSKMatAA. Depressive symptoms under atypical neuroleptic treatment in schizophrenia. Acta Psychiatrica Scandinavica (Abstracts of 13th International Symposium for the Psychological Treatment of Schizophrenia and Other Psychoses (ISPS); 2000 Jun 5-9; Stavanger, Norway) 2000;Suppl 404:62-3. - PubMed
    1. Perro C, Lambert M, Moritz S, Krausz M, Naber D. A comparison of clinical outcome of four atypical neuroleptics in the treatment of schizophrenia. Pharmacopsychiatry (Abstracts of 21st Symposium of the Arbeitsgemeinschaft Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP); 1999 Oct 6-9; Nuremberg, Germany) 1999;5:201.
    1. Perro C, Naber D, Lambert M, Moritz S, Krause M. A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia. In: 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:13.
Pivac 2002 {published data only}
    1. Pivac N, Muck-Seler D, Jakovljevic M, Sagud M, Mihaljevic-Peles A, Junaci S. The effects of olanzapine or fluphenazine on peripheral biochemical markers in schizophrenic patients. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada) 2002;Suppl 1:S184.
Rasmussen 2016 {published data only}
    1. Rasmussen SA, Rosebush PI, Anglin RE, Mazurek MF, et al. The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine. Psychiatry Research 2016;241:72-7. [DOI: 10.1016/j.psychres.2016.04.097] - DOI - PubMed
Ratakonda 1998 {published data only}
    1. Ratakonda S, Miller CE, Gorman JM, Sharif ZA. Efficacy of a 12 week trial of olanzapine in treatment refractory schizophrenia or schizoaffective disorder. Schizophrenia Research 1998;29(1,2):150. [CSG NO. 4079]
Reus 1997 {published data only}
    1. Kerwin R. Olanzapine. Lancet 1997;350:594. - PubMed
    1. Reus VI. Olanzapine: a novel atypical neuroleptic agent. Lancet 1997;349:1264-5. - PubMed
Rosebush 2000 {published data only}
    1. Rosebush P, Mazurek M. Olanzapine versus haloperidol in randomized trials of the first-episode patients with schizophrenia. Stanley Foundation Research Awards - 2000 ResearchAward Recipients (http://www.stanleyresearch.org/) 2000 (accessed February 2001).
Sacchetti 2003 {published data only}
    1. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, et al. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study. In: 16th European College of Neuropsychopharmacology (ECNP), 2003 Sep 20-24, Prague, Czech Republic. 2003. [EMBASE: 2003409683]
    1. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, et al. Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study. Journal of the European College of Neuropsychopharmacology 2003;13(4):S350. [P.2.162]
Sacristan (HGGS) {published data only}
    1. Sacristan JA. Doses of olanzapine, risperidone, and haloperidol in clinical practice: results of a prospective pharmaco-epidemiological study (efeso). Schizophrenia Research (Abstracts of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos, Switzerland) 2000;1:188-9.
Sangar 1998 (HGEH) {published data only}
    1. Sanger T M, Tohen M, Tollefson GD, McElroy SL, Greaney MG, Toma V. Olanzapine vs placebo in the treatment of acute mania. Schizophrenia Research (9th Biennial Winter Workshop on Schizophrenia, 1998 Feb 7-13, Davos, Switzerland) 1998;1,2:152.
    1. Sanger T, Tohen M, Tollefson GD, Jacobs T. Olanzapine versus placebo in rapid-cycling bipolar disorder. In: Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998. 1998.
    1. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Journal of Affective Disorders 2003;73(1-2):155-61. - PubMed
    1. Toben M, Zarate C Jr, Sanger IM. A placebo-controlled trial of olanzapine in psychotic or non-psychotic acute mania. Schizophrenia Research 1998;29(1,2):204. [MEDLINE: ]
    1. Tohen M, Jacobs T, Gannon KS, Sanger TM, Greaney M, Toma V, et al. Olanzapine: acute and long term efficacy in bipolar I patients. Schizophrenia Research 2000;41(1):192. [MEDLINE: ]
Sayers 2005 {published data only}
    1. Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. Journal of Nervous and Mental Disease 2005;193(6):379-86. [DOI: 10.1097/01.nmd.0000165089.14736.bf] [PMID: ] - DOI - PubMed
Sharma 2003 {published data only}
    1. Sharma M. Efficacy and safety of olanzapine versus haloperidol in schizophrenic patients in India. http://www.kgmcindia.edu/departments/psychiatry/psychiatry_fac_res.htm 2003. [MEDLINE: ]
Sheitman 1997 {published data only}
    1. Sheitman BB, Lindgren JC, Early J, Sved M. High dose olanzapine for treatment-refractory schizophrenia. American Journal of Psychiatry 1997;154(11):1626. - PubMed
Sheitman 2000 {published data only}
    1. Sheitman B. Olanzapine versus risperidone for people with schizophrenia hospitalized after a relapse. Stanley Foundation Research Awards - 2000 Research Award Recipients (http://www.stanleyresearch.org/) 2000 (accessed February 2001).
Sikich 2004 {published data only}
    1. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29(1):133-45. [EMBASE: 2004025276; 14583740 PMID] - PubMed
    1. Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, et al. Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth. In: 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico. 1999.
Smarek 2003 {published data only}
    1. Sramek JJ, Cutler NR, Shiovitz T. The effect of antipsychotics on plasma lipids. Journal of Clinical Psychopharmacology 2003;23(6):679-80. [DOI: 10.1097/01.jcp.0000096252.95165.a1] - DOI - PubMed
Smelson 2003 {published data only}
    1. Smelson DA, Ziedonis DM, Williams JA, Losonczy MF, Williams J, Kaune M. A double-blind trial of olanzapine reduces cue-elicited cocaine craving and relapses. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[NR692]]
Smith 1998 {published data only}
    1. Smith RC, Nigam S, Stern A, Infante M, Mehta R. Olanzapine in chronic nonresponding schizophrenia: effects on psychopathology and neurocognitive function. In: 21st Congress of Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland, UK. 1998. [CSG NO. 3628]
Smith 2001 {published data only}
    1. Smith RC, Infante M, Singh A, Garlapati V, Ali A. Response of chronic nonresponding schizophrenic patients to olanzapine: clinical and neurocognitive effects. Department Psychiatry, NYU Medical School & Manhattan Psychiatric Center 2001;unknown:-.
    1. Smith RC, Infante M, Singh A, Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. International Journal of Neuropsychopharmacology 2001;4(3):239-50. [DOI: ] - PubMed
    1. Smith RC, Lindenmayer J-P, Khandat A, Infante M, Singh A. Olanzapine affects neurocognitive function in medication-refractory schizophrenia. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
    1. Smith RC, Lindenmayer J-P, Khandat A, Infante M, Singh A. Olanzapine affects neurocognitive function in medication-refractory schizophrenia. In: Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA. Marathon Multimedia, 2001. [MEDLINE: ]
Soutullo 1998 {published data only}
    1. Soutullo CA, Sorter MT, Foster KD, McElroy SL, Keck PE. Olanzapine in the treatment of adolescent acute mania: preliminary report of seven cases. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Stephenson 2000 {published data only}
    1. Stephenson J. Delay in treating schizophrenia may narrow therapeutic window of opportunity. JAMA 2000;283(16):2091-2. - PubMed
Sun 2022 {published data only}
    1. Sun Y, Zhang Y, Lu Z, Yan H, Guo L, Liao Y, et al. Longitudinal network analysis reveals interactive change of schizophrenia symptoms during acute antipsychotic treatment. Schizophrenia Bulletin 2022;49(1):208–17. [DOI: 10.1093/schbul/sbac131] [PMID: ] - DOI - PMC - PubMed
Szafranski 1999 {published data only}
    1. Szafranski T, Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, et al. Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine. In: Journal of the European College of Neuropsychopharmacology. 1999:S273. [MEDLINE: ]
Tamura 1996 (F1D‐JE) {published data only}
    1. Tamura RN, Tanaka Y, Satoh K, Takahashi M. Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial. Journal of Biopharmacological Statistics 1996;6:127-37. - PubMed
Tang 2003 {published data only}
    1. Tang T, Meltzer HY. Olanzapine causes greater increases in serum lipids than risperidone. Schizophrenia Research 2003;60:367. [EMBASE: 2003241517]
Tang 2004 {published data only}
    1. Tang Y. A controlled study of olanzapine in treating positive symptoms of schizophrenia. Heath Psychology Journal 2004;12(5):390-1.
Tohen 2000b (HGGW) {published data only}
    1. Tohen M, Jacobs T, Toma V, Francis J, Zhang F, Gannon KS, et al. Is olanzapine a mood stabilizer? Schizophrenia Research 2000;41(1):193-4. [MEDLINE: ]
    1. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Archives of General Psychiatry 2000;57(9):841-9. - PubMed
Tran 1998 (HGEJ) {published data only}
    1. Tran PV, Tohen M, Mazzoti G, Silva C, Ospina J, Gattaz WF, et al. Switching psychotic patients with symptomatic extrapyramidal symptoms from haloperidol to olanzapine: results of a multi-center, collaborative trial in Latin America. In: 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998. 1998.
Trandafir 1998 {published data only}
    1. Trandafir AI, Berk M, Brook S. Olanzapine versus haloperidol in cannabis induced psychosis: a randomised double-blind trial. In: Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998. 1998.
Tsuang 2002 {published data only}
    1. Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. Journal of Clinical Psychiatry 2002;63(12):1180. - PubMed
Uzun 2002 {published data only}
    1. Uzun S, Folnegovic-Smalc V, Mimica N, Ljubin T, Makaric G, Ivezic S, et al. Ziprasidone clinical trials conducted in Croatia. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;3 Suppl 1:182.
Uzun 2006 {published data only}
    1. Uzun S, Kozumplik O, Mimica N, Folnegović-Šmalc V. Treatment with six different antipsychotics: evaluation by scale for the assessment of negative symptoms (SANS). In: Schizophrenia Research (Abstracts of the in XIIIth Biennial Winter Workshop on Schizophrenia). 2006.
Villari 2008 {published data only}
    1. Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008;32(2):405-13. - PubMed
Volavka 2002 {published data only}
    1. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2002;159(6):1018-28. [MEDLINE: ] [Volavka study (hostility study)] - PubMed
    1. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder. Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia) 2002;3 Suppl 1:195.
    1. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman J-PLB, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey) 2001;3:256.
    1. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, McEvoy J, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services 2001;52(11):1510-4. - PubMed
    1. Citrome LL, Volavka J, Czobor P, Nolan K, Lieberman JA, Lindenmayer J-P, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[NR221]] - PubMed
Voruganti 2002 {published data only}
    1. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al. Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study. Schizophrenia Research 2002;57(2-3):201-8. - PubMed
Wang 2018 {published data only}
    1. Wang Q, Wu HM, Yue W, Yan H, Zhang Y, Tan L, et al. Effect of damaging rare mutations in synapse-related gene sets on response to short-term antipsychotic medication in Chinese patients with schizophrenia: a randomized clinical trial. JAMA Psychiatry 2018;75(12):1261-9. [DOI: 10.1001/jamapsychiatry.2018.3039] - DOI - PMC - PubMed
Woods 2002 (HGGF) {published data only}
    1. McGlashan TH, Miller TJ, Zipursky RB, Woods SW, Perkins DO, Hawkins KA, et al. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[SYMPOSIUM]No. 39]
    1. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research 2003;61(1):7-18. [MEDLINE: ] [PMID 12648731] - PubMed
    1. McGlashan TH, Zipursky RB, Perkins DO, Addington J, Woods SW, Miller TJ, et al. Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results. Schizophrenia Research 2003;60:295. [EMBASE: 2003241517]
    1. McGlashan TH, Zipursky RB, Perkins DO, Addington JM, Woods SW, Lindborg S, et al. Olanzapine versus pbo for the schizophrenic prodrome: one-year results. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[NR584]]
    1. McGlashan TH, Zipursky RB, Perkins DO, Addington JM, Woods SW, Lindborg S, et al. Olanzapine versus pbo for the schizophrenic prodrome: one-year results. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA. 2003. [[NR584]]
Woodward 2001 {published data only}
    1. Woodward ND, Purdon SE, David SR, Stip E. Procedural learning over six months double blind treatment with haloperidol, risperidone or olanzapine. Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada) 2001;1-2 Suppl:125. [MEDLINE: ]
Wright 2003 (HGAB) {published data only}
    1. King KG, Wright P, Meehan K, Birkett M, David SR, Taylor CC. Transition from intramuscular to oral olanzapine. In: XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [now published lwad author wright part of (HGAB) clinical therapeutics 2003, vol 25, p420-28]
    1. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian Journal of Psychiatry 2003;48:11. [EMBASE: 2003409683] - PubMed
    1. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka KF-HI, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 2003;48(11):716-21. [PMID 14733451] - PubMed
    1. Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 2003;25(5):1420-8. - PubMed
    1. Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris PBA. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 2003;25(5):1420-8. [MEDLINE: ] [PMID 12867218] - PubMed
Wudarsky 1999 {published data only}
    1. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 1999;9(4):239-45. [MEDLINE: ] - PubMed
Yagdiran 2000 {published data only}
    1. Yagdiran O, Krausz M. Depressive symptoms under atypical neuroleptic treatment in schizophrenia.. Der Nervenarzt (Congress of the Deutsche Gesselschaft fur Psychiatrie, Psychotherapie und Nervenheilkunde: "Psychiatrie im Jahr 2000 - die europaische Perspektive", 2000 September 20-23, Aachen, Germany) 2000;71(Suppl 1):S135-6.
Yan 2022 {published data only}
    1. Yan VK, Haendler M, Lau H, Li X, Lao K, Tsui SH, et al. Cost-effectiveness of midazolam versus haloperidol versus olanzapine for the management of acute agitation in the accident and emergency department. Value in Health 2022;25(7):1099-106. [DOI: 10.1016/j.jval.2021.11.1374] - DOI - PubMed
Zabotina 2020 {published data only}
    1. Zabotina A, Grunina M, Nasyrova R, Taraskina A. Reduction of 5HTR2A protein level in peripheral blood lymphocytes during antipsychotic therapy is associated with absence of common side effects. European Neuropsychopharmacology 2020;40(Suppl. 1):S288-9.
Zhang 1999 {published and unpublished data}
    1. Zhang F, Tran PV, Taylor C, Hwu GH, Chen YS, Chang WH, et al. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong. In: World Psychiatric Association. Hamburg, Germany. 1999.
Ziherl (HGCZ) 1999 {unpublished data only}
    1. Ziherl S, Novak G, Kores-Plesnicar B, Kosorok M, Juch H, Dossenbach M. Efficacy and safety of olanzapine in the treatment of schizophrenic, schizophreniform and schizoaffective patients in Slovenia. In: ECNP. London, England, UK. 1999.

Additional references

Abel 2010
    1. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. International Review of Psychiatry 2010;22(5):417-28. [DOI: 10.3109/09540261.2010.515205] - DOI - PubMed
Adams 2006
    1. Adams CE, Tharyan P, Coutinho ES, Stroup TS. The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry 2006;189(5):391-2. [DOI: 10.1192/bjp.bp.106.029983] - DOI - PubMed
Adams 2013
    1. Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No: CD003082. [DOI: 10.1002/14651858.CD003082.pub3] - DOI - PMC - PubMed
Addington 1993
    1. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry 1993;22:39–44. - PubMed
Alahdab 2012
    1. Alahdab F, Alhalabi O, Attwa G, Mousa Basha G, Adams CE. Olanzapine discontinuation for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No: CD009693. [DOI: 10.1002/14651858.CD009693] - DOI
Alderson 2004
    1. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’ Handbook 4.2.1 [updated December 2003]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. - PMC - PubMed
AMDP‐5 1981
    1. Arbeltsgemelnschaft fur methodik und dokumentation inder psychiatrie (AMDP) [Association for Methodology and Documentation in Psychiatry]. Das AMDP-System: Manualzur Dokumentation Psychiatricher Befunde. Berlin, 1981.
Andreasen 1983
    1. Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1982;39:784–8. - PubMed
Asenjo Lobos 2010
    1. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No: CD006633. [DOI: 10.1002/14651858.CD006633.pub2] - DOI - PMC - PubMed
Asenjo‐Lobos 2018
    1. Asenjo-Lobos C, Fonseca C, Leucht S, Arancibia M, Cortés‐Jofré M. Clozapine versus olanzapine for people with schizophrenia. Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No: CD013219. [DOI: 10.1002/14651858.CD013219] - DOI
Asenjo‐Lobos 2018a
    1. Asenjo-Lobos C, Cortes-Jofre M, Fonseca C, Leucht S, Madrid E, Bonfill Cosp X. Clozapine versus risperidone for people with schizophrenia. Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No: CD013221. [DOI: 10.1002/14651858.CD013221] - DOI
Asmal 2013
    1. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No: CD006625. [DOI: 10.1002/14651858.CD006625.pub3] - DOI - PubMed
Bagnall 2000
    1. Bagnall AM, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No: CD001945. [DOI: 10.1002/14651858.CD001945] - DOI - PubMed
Barnes 1989
    1. Barnes TR. A rating scale for drug-induced akathisia. BritishJournal of Psychiatry 1989;154:672–6. - PubMed
Belgamwar 2005
    1. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD003729. [DOI: 10.1002/14651858.CD003729.pub2] - DOI - PMC - PubMed
Bhattacharjee 2016
    1. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No: CD012073. [DOI: 10.1002/14651858.CD012073] - DOI
Blackmore 2020
    1. Blackmore R, Boyle JA, Fazel M, Ranasinha S, Gray KM, Fitzgerald G, et al. The prevalence of mental illness in refugees and asylum seekers: a systematic review and meta-analysis. PLOS Medicine 2020;17(9):e1003337. [DOI: 10.1371/journal.pmed.1003337] [PMID: PMID: 32956381] - DOI - PMC - PubMed
Bland 1997
    1. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315(7108):600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PMID: ] - PubMed
Bola 2011
    1. Bola JR, Kao D, Soydan H, Adams CE. Antipsychotic medication for early episode schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No: CD006374. [DOI: 10.1002/14651858.CD006374.pub2] - DOI - PMC - PubMed
Bosnjak 2019
    1. Bosnjak Kuharic D, Kekin I, Hew J, Rojnic Kuzman M, Puljak L. Interventions for prodromal stage of psychosis. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No: CD012236. [DOI: 10.1002/14651858.CD012236.pub2] - DOI - PMC - PubMed
Bymaster 1999
    1. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro. Schizophrenia Research 1999;37(1):107-22. [DOI: 10.1016/S0920-9964(98)00146-7] - DOI - PubMed
Carpenter 1984
    1. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388–96. - PubMed
Carpenter 1994
    1. Carpenter WTJ, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330(10):681–90. [DOI: 10.1056/NEJM199403103301006] [PMID: ] - DOI - PubMed
Charlson 2018
    1. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia Bulletin 2018;44(6):1195-203. [DOI: 10.1093/schbul/sby058] - DOI - PMC - PubMed
Chisholm 2016
    1. Chisholm D, Burman-Roy S, Fekadu A, Kathree T, Kizza D, Luitel NP, et al. Estimating the cost of implementing district mental healthcare plans in five low-and middle-income countries: the PRIME study. British Journal of Psychiatry 2016;208(s56):s71-8. [DOI: 10.1192/bjp.bp.114.153866] - DOI - PMC - PubMed
Chouinard 1980
    1. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science;1980(7):233.
COSTART 1990
    1. Food and Drug Administration. COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms. 2nd edition. Rockville MD Food and Drug Administration, 1990.
Datta 2012
    1. Datta SS, Kumar A, Wright SD, Russell P. Typical antipsychotics for psychosis in adolescents. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No: CD009539. [DOI: 10.1002/14651858.CD009539] - DOI - PMC - PubMed
de Haan 2002a
    1. Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale (SWN) and the SubjectiveDeficit Syndrome Scale (SDSS). Psychopharmacology (Berl) 2002;162:24–8. - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta-analyses of binary data. In: Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Deeks 2011
    1. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
DeSilva 2006
    1. DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No: CD001948. [DOI: 10.1002/14651858.CD001948.pub2] - DOI - PMC - PubMed
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9. - PubMed
Dold 2015
    1. Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No: CD009831. [DOI: 10.1002/14651858.CD009831.pub2] - DOI - PMC - PubMed
Donnelly 2013
    1. Donnelly L, Rathbone J, Adams CE. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD001951. [DOI: 10.1002/14651858.CD001951.pub2] - DOI - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971-80. - PubMed
Drugs 2020
    1. Haloperidol - usual adult dose for schizophrenia. https://www.drugs.com/dosage/haloperidol.html#Usual_Adult_Dose_for_Schiz... (last updated 11 February 2020).
Duggan 2005
    1. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S, et al. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD001359. [DOI: 10.1002/14651858.CD001359.pub2] - DOI - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. - PMC - PubMed
El‐Sayeh 2006
    1. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD004578. [DOI: 10.1002/14651858.CD004578.pub3] - DOI - PMC - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JP, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Elis 2013
    1. Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clinical Psychology Review 2013;33(8):914-28. [DOI: 10.1016/j.cpr.2013.07.001] - DOI - PMC - PubMed
Essali 2009
    1. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No: CD000059. [DOI: 10.1002/14651858.CD000059.pub2] - DOI - PMC - PubMed
Essali 2019
    1. Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Diaa Aldeen MR, Marwa ME, et al. Haloperidol discontinuation for people with schizophrenia. Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No: CD011408. [DOI: 10.1002/14651858.CD011408.pub2] - DOI - PMC - PubMed
Fenton 2007
    1. Fenton M, Rathbone J, Reilly J. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD001944. [DOI: 10.1002/14651858.CD001944.pub2] - DOI - PMC - PubMed
Fleischhacker 1989
    1. Fleischhacker WW, Bergmann KJ, Perovich R, PestreichLK, Borenstein M, Lieberman JA, et al. The Hillside Akathisia Scale: a new rating instrument for neuroleptic induced akathisia.. Psychopharmacology Bulletin 1989;25(2):222-6. [MEDLINE: ] - PubMed
Fleischhacker 1994
    1. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scandinavica. Supplementum 1994;382:11-5. [PMID: ] - PubMed
Folstein 1975
    1. Folstein NF, Folstein SE, McHugh PR. Mini-Mental State:a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98. - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10. - PubMed
Gilbody 2016
    1. Gilbody S, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No: CD002306. [DOI: 10.1002/14651858.CD002306.pub2] - DOI - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 6 August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.
Green 2004
    1. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004;56(5):301-7. [DOI: 10.1016/j.biopsych.2004.06.023] - DOI - PubMed
Gulliford 1999
    1. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83. - PubMed
Guy 1976
    1. Guy U. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. National Institute of Mental Health 1976;unknown:-.
Hamann 2003
    1. Hamann J, Kissling W, Leucht S, Rummel-Kluge C. New generation antipsychotics for first episode schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No: CD004410. [DOI: 10.1002/14651858.CD004410] - DOI - PubMed
Hamilton 1960
    1. Hamilton M. A rating scale for depression. Journal of Neurology. Neurosurgery and Psychiatry 1960;23:56–62. - PMC - PubMed
Hamilton 1969
    1. Hamilton A. Diagnosis and Rating of Anxiety. BritishJournal of Psychiatry 1969;S3:76–9.
Hanafi 2017
    1. Hanafi I, Arafat S, Al Zayed L, Sukkar M, Albeirakdar A, Krayem D, et al. Haloperidol (route of administration) for people with schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No: CD012833. [DOI: 10.1002/14651858.CD012833] - DOI
Helfer 2015
    1. Helfer B, Rothe PH, Leucht S, Samara MT. Switching antipsychotic for non response in schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD011885. [DOI: 10.1002/14651858.CD011885] - DOI - PMC - PubMed
Herath 2009
    1. Herath Mudiyanselage I, Alagarsamy J, Kachhap S, Jayaram MB. Olanzapine depot for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD007947. [DOI: 10.1002/14651858.CD007947] - DOI
Herath Mudiyanselage 2009
    1. Herath Mudiyanselage I, Alagarsamy J, Kachhap S, Jayaram MB. Olanzapine depot for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD007947. [DOI: 10.1002/14651858.CD007947] - DOI
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2008
    1. Higgins JP, Green S. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. [DOI: 10.1002/9780470712184] - DOI
Higgins 2011a
    1. Higgins JP, Green S. Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Higgins 2011b
    1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. [DOI: 10.1136/bmj.d5928] [PMID: ] - DOI - PMC - PubMed
Hogan 1983
    1. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983;13:177–83. - PubMed
Huf 2016
    1. Huf G, Alexander J, Gandhi P, Allen MH. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No: CD005146. [DOI: 10.1002/14651858.CD005146.pub3] - DOI - PMC - PubMed
Huhn 2019
    1. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019;394(10202):939-51. [DOI: 10.1016/S0140-6736(19)31135-3] - DOI - PMC - PubMed
Hunter 2003
    1. Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No: CD000440. [DOI: 10.1002/14651858.CD000440] - DOI - PMC - PubMed
Huston 1996
    1. Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996;347(9007):1024-6. - PubMed
Hutton 2009
    1. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30. [PMID: ] - PubMed
Inada 1996
    1. Inada M. Evaluation and Diagnosis of Drug-Enduced Extrapyramidal Symptoms: Commentary on the DIEPSS and guide to its usage. Tokyo: Seiwa Shoten, 1996.
Jaaskelainen 2013
    1. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia bulletin 2013;39(6):1296-306. [DOI: 10.1093/schbul/sbs130] - DOI - PMC - PubMed
Jayaram 2006
    1. Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD005237. [DOI: 10.1002/14651858.CD005237.pub2] - DOI - PubMed
Jones 2009
    1. Jones L, Asare JB, El Masri M, Mohanraj A, Sherief H, Van Ommeren M, et al. Severe mental disorders in complex emergencies. Lancet 2009;374(9690):654-61. [DOI: 10.1016/S0140-6736(09)61253-8] - DOI - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Kennedy 2007
    1. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD004027. [DOI: 10.1002/14651858.CD004027.pub2] - DOI - PMC - PubMed
Khanna 2014
    1. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No: CD006569. [DOI: 10.1002/14651858.CD006569.pub5] - DOI - PMC - PubMed
Komossa 2009
    1. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmid F, Lewis R, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD006752. [DOI: 10.1002/14651858.CD006752.pub2] - DOI - PMC - PubMed
Komossa 2009a
    1. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No: CD006627. [DOI: 10.1002/14651858.CD006627.pub2] - DOI - PMC - PubMed
Komossa 2010
    1. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No: CD006654. [DOI: 10.1002/14651858.CD006654.pub2] - DOI - PMC - PubMed
Komossa 2010a
    1. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD006624. [DOI: 10.1002/14651858.CD006624.pub2] - DOI - PMC - PubMed
Komossa 2011
    1. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No: CD006626. [DOI: 10.1002/14651858.CD006626.pub2] - DOI - PMC - PubMed
Kudo 1999
    1. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol. Clinical pharmacokinetics 1999;37(6):435-56. [DOI: 10.2165/00003088-199937060-00001] - DOI - PubMed
Kumar 2013
    1. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD009582. [DOI: 10.1002/14651858.CD009582.pub2] - DOI - PMC - PubMed
Latifeh 2019
    1. Latifeh Y, Mohsen M, Mohamad S, Nassif T. Olanzapine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No: CD013266. [DOI: 10.1002/14651858.CD013266] - DOI
Lefebvre 2019
    1. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M, et al. Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2 edition. John Wiley and Sons, 2019:67-107. [DOI: 10.1002/9781119536604.ch4] - DOI
Lehman 1983
    1. Lehman A. The well being of chronic mental patients:assessing their quality of life. Archives of General Psychiatry 1983;40:369–73. - PubMed
Leon 2006
    1. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PMID: ] - PubMed
Leucht 1999
    1. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999;35(1):51-68. [DOI: 10.1016/S0920-9964(98)00105-4] - DOI - PubMed
Leucht 2005
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophrenia Research 2005;79(2-3):231-8. [DOI: 10.1016/j.schres.2005.04.008] - DOI - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PMID: ] - PubMed
Leucht 2005b
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophrenia Research 2005;79(2-3):231-8. [PMID: ] - PubMed
Leucht 2012
    1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub2] - DOI - PubMed
Leucht 2018
    1. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD004278. [DOI: 10.1002/14651858.CD004278.pub2] - DOI - PMC - PubMed
Leucht 2020
    1. Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. American Journal of Psychiatry 2020;177(4):342-53. [DOI: 10.1176/appi.ajp.2019.19010034] - DOI - PubMed
Lewis 2005
    1. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No: CD001715. [DOI: 10.1002/14651858.CD001715.pub2] - DOI - PMC - PubMed
Li 2019
    1. Li Y, Du C, Jiaxiang N, Liqiang Y, Qi F. Olanzapine versus placebo for people with schizophrenia. Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No: CD013310. [DOI: 10.1002/14651858.CD013310] - DOI
Lingjaerde 1987
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. ActaPsychiatrica Scandinavica Supplementum 1987;76(334):100. - PubMed
Lopez‐Munoz 2009
    1. Lopez-Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain research bulletin 2009;79(2):130-41. [DOI: 10.1016/j.brainresbull.2009.01.005] - DOI - PubMed
Lund 2018
    1. Lund C, Brooke-Sumner C, Baingana F, Baron EC, Breuer E, Chandra P, et al. Social determinants of mental disorders and the Sustainable Development Goals: a systematic review of reviews. Lancet Psychiatry 2018;5(4):357-69. [DOI: 10.1016/S2215-0366(18)30060-9] [PMID: ] - DOI - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52. - PubMed
Marshall 2011
    1. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No: CD004718. [DOI: 10.1002/14651858.CD004718.pub3] - DOI - PMC - PubMed
McGrath 2004
    1. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2004;2:13. [DOI: 10.1186/1741-7015-2-13] - DOI - PMC - PubMed
McGrath 2008
    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30(1):67-76. [DOI: ] - PubMed
Melander 2003
    1. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b (i) ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326(7400):1171-3. [DOI: 10.1136/bmj.326.7400.1171] - DOI - PMC - PubMed
Miller 2010
    1. Miller KE, Rasmussen A. War exposure, daily stressors, and mental health in conflict and post-conflict settings: bridging the divide between trauma-focused and psychosocial frameworks. Social Science & Medicine 2010;70(1):7-16. [DOI: 10.1016/j.socscimed.2009.09.029] - DOI - PubMed
Montgomery 1979
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9. - PubMed
Montgomery 2004
    1. Montgomery JH, Byerly M, Carmody T, LiB, Miller DR, Varghese F, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 2004;25(6):598-612. [DOI: 10.1016/j.cct.2004.09.002] - DOI - PubMed
Ostinelli 2017
    1. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No: CD009377. [DOI: 10.1002/14651858.CD009377.pub3] - DOI - PMC - PubMed
Ostuzzi 2017
    1. Ostuzzi G, Barbui C, Hanlon C, Chatterjee S, Eaton J, Jones L, et al. Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance. BMC Medicine 2017;15(1):197-204. [DOI: 10.1186/s12916-017-0960-z] - DOI - PMC - PubMed
Ostuzzi 2022a
    1. Ostuzzi G, Gastaldon C, Papola D, Barbui C. Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries. Epidemiology and Psychiatric Sciences 2022;31:e34. [PMID: ] - PMC - PubMed
Ostuzzi 2022b
    1. Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry 2022;21(2):295-307. [DOI: 10.1002/wps.20972] [PMID: ] - DOI - PMC - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
Parrott 1980
    1. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology 1980;71:173-9. - PubMed
Priebe 1999
    1. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry 1999;45:7-12. - PubMed
Quraishi 1999
    1. Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No: CD001361. [DOI: 10.1002/14651858.CD001361] - DOI - PMC - PubMed
Ray 2017
    1. Ray S, Ray A, Gopi A, Hunter R. Haloperidol versus risperidone for schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No: CD012728. [DOI: 10.1002/14651858.CD012728] - DOI
Review Manager 2014 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Reynolds 2010
    1. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacology & Therapeutics 2010;125(1):169-79. [DOI: 10.1016/j.pharmthera.2009.10.010] - DOI - PubMed
Roberts 2021
    1. Roberts MT, Shokraneh F, Sun Y, Groom M, Adams CE. Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies. Evidence-Based Mental Health 2021;24:62-9. [DOI: 10.1136/ebmental-2020-300151] - DOI - PMC - PubMed
Schneider‐Thoma 2022
    1. Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 2022;399:824-36. [DOI: 10.1016/S0140-6736(21)01997-8] [PMID: ] - DOI - PubMed
Schott 2010
    1. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Ärzteblatt International 2010;107(16):279. [DOI: 10.3238/arztebl.2010.0279] - DOI - PMC - PubMed
Schotte 1993
    1. Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Research 1993;631(2):191-202. [DOI: 10.1016/0006-8993(93)91535-Z] - DOI - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama 1995;273(5):408-12. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Settle 1983
    1. Settle EC, Ayd FJ. Haloperidol: a quarter century ofexperience. Journal of Clinical Psychiatry 1983;44:440–8. [PMID: ] - PubMed
Shirzadi 2006
    1. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harvard Review of Psychiatry 2006;14(3):152-64. [DOI: 10.1080/10673220600748486] - DOI - PubMed
Shokraneh 2017
    1. Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis. BioImpacts 2017;7(4):209-17. [DOI: 10.15171/bi.2017.25] - DOI - PMC - PubMed
Shokraneh 2019
    1. Shokraneh F, Adams CE. Study-based registers reduce waste in systematic reviewing: discussion and case report. Systematic Reviews 2019;8:129. [DOI: 10.1186/s13643-019-1035-3] - DOI - PMC - PubMed
Shokraneh 2020
    1. Shokraneh F, Adams CE. Cochrane Schizophrenia Group’s study-based register of randomized controlled trials: development and content analysis. Schizophrenia Bulletin Open 2020;1:sgaa061. [DOI: 10.1093/schizbullopen/sgaa061] - DOI
Shokraneh 2021
    1. Shokraneh F, Adams CE. Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis. Health Information and Libraries Journal 2021;In Press:In Press. [DOI: 10.1111/hir.12366] - DOI - PubMed
Silveira 2002
    1. Silveira da Mota Neto JI, Soares BGO, Silva de Lima M. Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No: CD001357. [DOI: 10.1002/14651858.CD001357] - DOI - PMC - PubMed
Simpson 1970
    1. Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11–9. - PubMed
Srisurapanont 2004
    1. Srisurapanont M, Maneeton B, Maneeton N, Lankappa S, Gandhi R. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No: CD000967. [DOI: 10.1002/14651858.CD000967.pub2] - DOI - PMC - PubMed
Sterne 2011
    1. Sterne JA, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Subramanian 2010
    1. Subramanian S, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W, et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No: CD006628. [DOI: 10.1002/14651858.CD006628.pub3] - DOI - PMC - PubMed
Suttajit 2013
    1. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No: CD007815. [DOI: 10.1002/14651858.CD007815.pub2] - DOI - PubMed
Tardy 2014
    1. Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No: CD009268. [DOI: 10.1002/14651858.CD009268.pub2] - DOI - PMC - PubMed
Taylor 2018
    1. Taylor D, Barnes, TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 13th edition. John Wiley & Sons, 2018.
Tong 2018
    1. Tong Z, Li F, Ogawa Y, Watanabe N, Furukawa TA. Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study. BMC Medical Research Methodology 2018;18(1):96. [DOI: 10.1186/s12874-018-0554-2] - DOI - PMC - PubMed
Turner 2012
    1. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLOS Medicine 2012;9(3):-. [DOI: 10.1371/journal.pmed.1001189] - DOI - PMC - PubMed
Tuunainen 2000
    1. Tuunainen A, Wahlbeck K. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No: CD000966. [DOI: 10.1002/14651858.CD000966] - DOI - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. - PubMed
Ware 1992
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30:473-83. - PubMed
Weston‐Green 2013
    1. Weston-Green K, Huang XF, Deng C, et al. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS drugs 2013;27(12):1069-80. [DOI: 10.1007/s40263-013-0115-5] - DOI - PubMed
WHO 1996
    1. World Health Organization. WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment: field trial version, December 1996 (No. WHOQOL-BREF). Available at https://apps.who.int/iris/handle/10665/63529 1996.
WHO 2021
    1. World Health Organization. Mental health atlas 2020. Available at https://apps.who.int/iris/handle/10665/345946.
WHO 2022
    1. World Health Organization. World mental health report: transforming mental health for all. Available at https://www.who.int/publications/i/item/9789240049338.
WHO 2023
    1. World Health Organization. WHO 24th Expert Committee on Selection and Use of Essential Medicines. Available at www.who.int/groups/expert-committee-on-selection-and-use-of-essential-me....
WHO 2023b
    1. World Health Organization. WHO model list of essential medicines. Available at https://apps.who.int/iris/handle/10665/345533 2023;23rd list:66.
Wright 2004
    1. Wright SD, Russell P. Interventions for psychosis in adolescents. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No: CD004965. [DOI: 10.1002/14651858.CD004965] - DOI
Wu 2009
    1. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10(1):46. [https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-10-46] - PMC - PubMed
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
Xiberas 2001
    1. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'h C, Maziere B, et al. Extrastriatal and striatal D 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 2001;179(6):503-8. [DOI: 10.1192/bjp.179.6.503] - DOI - PubMed
Yang 2017
    1. Yang HL, Zheng JG, Li B, Zhao S, Zheng W. Aripiprazole versus ziprasidone for schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No: CD012811. [DOI: 10.1002/14651858.CD012811] - DOI
Zare 2017
    1. Zare M, Bazrafshan A. Chlorpromazine versus metiapine for schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No: CD011655. [DOI: 10.1002/14651858.CD011655.pub2] - DOI - PMC - PubMed

References to other published versions of this review

Ibragimov 2019
    1. Ibragimov K, Keane G, Carreño Glaría C, Cheng J, Llosa A. Haloperidol versus olanzapine for people with schizophrenia. Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No: CD013425. [DOI: 10.1002/14651858.CD013425] - DOI - PMC - PubMed

Associated data

LinkOut - more resources